. Introduction {#s01}
==============

Hepatocellular carcinoma (HCC) is the most frequent primary liver malignancy. It is ranked the third-most common cause of cancer-related deaths worldwide^[@b1]^. In China, the incidence of liver cancer as well as deaths due to liver cancer are high, and they account for approximately 50% of the total cases and deaths across the globe^[@b2]^. Patients with HCC who are diagnosed at an early stage have the best chance of receiving effective treatments, such as resection, ablation, or transplantation, leading to long-term disease-free survival^[@b1]^. However, tumors are generally detected either at an intermediate or an advanced stage, which limits clinical therapeutic options^[@b3]^. The 5-year recurrence risk can be as high as 70%, even in patients who undergo surgical resection. Most cases of recurrence occur within the first 2 years following surgery, and are due to tumor invasion and metastasis^[@b4]^.

Cytosolic phospholipase A2α (cPLA2α, also known as group IVA PLA2) is a member of the intracellular phospholipase A2 family. It is known for its high selectivity in catalyzing membrane phospholipids containing arachidonic acid (AA) at the *sn*-2 position^[@b5]^. Free AA, which is released, is rapidly metabolized into various bioactive eicosanoids, including hydroxy eicosatetraenoic acids, prostaglandins, and leukotrienes^[@b6]^. These metabolites play vital roles in tumorigenesis, tumor metastasis, and progression^[@b7]^. Previous studies conducted by us demonstrated that cPLA2α could promote epithelial-mesenchymal transition (EMT), thereby contributing to tumor metastasis in HCC and breast cancer *via* AA production^[@b8],\ [@b9]^.

Cancer metastasis comprises a series of successive biological events. In the first step, cancer cells detach from the primary tumor and invade the surrounding extracellular matrix (ECM) and stromal cell layers^[@b10]^. Therefore, the migration capability of cancer cells assumes importance during metastasis. One prominent structure involved in cell migration is integrin-based focal adhesion (FA), which plays a crucial role in determining dynamic cell-matrix interactions^[@b11]^. FA kinase (FAK) is a nonreceptor tyrosine kinase that participates in FA complex formation. Its dysregulation is found in various types of cancer in relation to tumor metastasis^[@b12]-[@b15]^. Paxillin, which is a structural protein of the FA complex, also contributes to metastasis^[@b16]^. Although involvement of cPLA2 in cell-matrix adhesion in the immune system has been reported^[@b17]^, the role of cPLA2α in HCC cell adhesion as well as the involvement of FAK or paxillin in this biological process remains largely unknown.

In this study, we investigated the effect of cPLA2α on the cell-matrix and cell-cell adhesion of HCC cells. Using phospho-protein microarray technology, we analyzed the phosphoproteome profiles of cPLA2α-knockdown and cPLA2α-overexpressing HepG2 cells. We identified 2 proteins, FAK and paxillin, in the FA pathway as downstream molecules of cPLA2α. We also explored the prognostic role of cPLA2α and p-FAK in patients with HCC.

. Materials and methods {#s02}
=======================

. Patients and follow-up {#s02.01}
------------------------

The tumor specimens used in the tissue microarray were obtained from 74 HCC patients who underwent surgical resection from January 2013 to January 2014 at the Tianjin Medical University Cancer Institute and Hospital. All tumor samples were histologically confirmed as HCC. All patients were staged in accordance with the 8th edition of TNM staging system based on AJCC. Informed consent was obtained from all patients involved. This study was conducted in accordance with the Declaration of Helsinki and approved by the Tianjin Medical University Cancer Institute and Hospital Ethics Committee. Post-surgical patient surveillance was conducted every 3 months *via* serum AFP and abdominal ultrasonography. Where recurrence was suspected, examination techniques were replaced with thoracoabdominal CT and abdominal magnetic resonance imaging (MRI) to confirm the diagnosis. Clinical data and follow-up results of these patients were recorded. No patient was lost during the follow-up period. The follow-up was updated to October 10, 2017. Eleven additional paired tumors and adjacent noncancerous tissues were collected from the HCC patients who had undergone surgical resection at our institute between 2014 and 2015, and used for western blot analysis.

. Phospho-protein profiling by Phospho Explorer Antibody Array analysis {#s02.02}
-----------------------------------------------------------------------

The Phospho Explorer Antibody Array (PEX100) was obtained from Full Moon Biosystems (Sunnyvale, CA, USA). Lysates of cPLA2α-knockdown as well as cPLA2α-overexpressing HepG2 cells were used as experimental samples. The detailed procedure was conducted as described previously^[@b18]^. The phosphorylation ratio of each phosphorylation site was calculated based on the following equation: phosphorylation ratio = phosphorylated molecules/unphosphorylated molecules. Phosphorylated proteins were considered as differentially expressed, once an increase (\> 1.18) or a decrease (\< 0.85) occurred in the expression level ratio in cPLA2α-knockdown HepG2 cells relative to cPLA2α-overexpressing HepG2 cells.

. Bioinformatics analysis {#s02.03}
-------------------------

The Database for Annotation, Visualization, and Integrated Discovery (DAVID) (https://david.ncifcrf.gov/) was used to identify significantly enriched Gene Ontology (GO) terms. We focused on the categories of biological process, molecular function, or cellular components, where those with a *P* \< 0.01 and a false discovery rate (FDR) \< 0.001 were classified as significantly enriched GO terms. The online functional annotation tool, DAVID, was also used for pathway enrichment analyses. Filtering criteria for significantly changed signaling pathways were a *P* \< 0.01 and an FDR \< 0.01. A map of the FA pathway showing annotated upregulation and downregulation of phosphorylated proteins was obtained using the Kyoto Encyclopedia of Genes and Genomes (KEGG) (https://www.kegg.jp/). Protein-protein interaction (PPI) network data were obtained using the Search Tool for Retrieval of Interacting Genes/Proteins (STRING) (http://www.string-db.org/) and then imported into Cytoscape v2.8.3 (http://www.cytoscape.org/) for network visualization.

. Statistical analysis {#s02.04}
----------------------

All statistical analyses were conducted using SPSS 19.0 (SPSS Inc., Chicago, IL). Continuous variables were compared between two groups *via* unpaired *t*-tests, while categorical variables were compared *via* the Mann-Whitney U test. Overall survival (OS) and disease-free survival (DFS) were calculated using the Kaplan-Meier method. The log-rank test was used for univariate analysis. Multivariable analysis for OS and DFS were performed by including all significant variables of the univariate analysis in a Cox proportional hazards regression analysis. All statistical tests were two tailed and statistical significance was set at *P* \< 0.05.

Details related to the other assays are described in the supplementary materials and methods.

. Results {#s03}
=========

. cPLA2α modulates cell-matrix and cell-cell adhesion in HepG2 cells {#s03.01}
--------------------------------------------------------------------

First, we successfully established stable suppression and overexpression of cPLA2α in HepG2 cell lines *via* the lentiviral infection system (**[Figure 1A](#Figure1){ref-type="fig"}**). It was observed that adherence to the plastic cell culture dish surface was significantly impaired by cPLA2α knockdown. Therefore, we inferred that cPLA2α may regulate the interaction between cells and the ECM. For verification purposes, we performed a cell adhesion assay, which revealed that the attachment rate of cPLA2α-downregulated HepG2 cells to fibronectin, at 5, 15, and 30 min was remarkably reduced compared to that of the control cells (**[Figure 1B](#Figure1){ref-type="fig"}**, left panel). In contrast, the number of adherent cells significantly increased in the cPLA2α-overexpressing HepG2 cells compared with the number in the control group (**[Figure 1B](#Figure1){ref-type="fig"}**, right panel).

![cPLA2α modulates cell-matrix and cell-cell adhesion in HepG2 cells. (A) The knockdown and overexpression efficiency of cPLA2α in HepG2 cells was examined by western blot. The abbreviation of cPLA2α-knockdown and cPLA2α-overexpressing HepG2 cells were KD and OE, respectively. The abbreviation of negative control of cPLA2α-knockdown and cPLA2α-overexpressing HepG2 cells were KD/SCR and OE/SCR, respectively. (B) KD/SCR, KD, OE/SCR and OE cells were seeded on twelve-well plates precoated with fibronectin. The number of adherent cells was counted in five random fields on every coverslip under microscopy (200 ×) at 5, 15, 30 min (^\*\*\*^*P* \< 0.001). (C) The strength of cell attachment to the substratum was measured by the percentage of detached cells at different time points with trypsin treatment. (D) The hanging-drop assay was performed on KD/SCR and KD cells with or without trituration. Cell aggregates of different sizes (represented by the number of cells per aggregate) were counted before and after trituration at the indicated incubation time points, and their proportions in each sample were shown in the bar graphs. Scale bar: 200 μm. (E) The hanging-drop assay was performed on OE/SCR and OE cells with or without trituration. Cell aggregates of different sizes (represented by the number of cells per aggregate) were counted before and after trituration at the indicated incubation time points, and their proportions in each sample were shown in the bar graphs. Scale bar, 200 μm. Data are represented as the mean ± SD. All experiments were repeated at least three times.](cbm-16-2-377-1){#Figure1}

Furthermore, we determined the effect of cPLA2α on the strength of HepG2 cell anchorage to a Matrigel-coated substratum *via* a cell detachment assay. The results indicated that cPLA2α-knockdown HepG2 cells detached after 13 min of exposure to trypsin whereas control cells detached only after 20 min of exposure to trypsin (**[Figure 1C](#Figure1){ref-type="fig"}**, left panel). By contrast, cPLA2α-overexpressing HepG2 cells detached following 25 min of exposure to trypsin, compared to the control cells that detached following 19 min of exposure (**[Figure 1C](#Figure1){ref-type="fig"}**, right panel).

Changes in cell-matrix adhesion are frequently accompanied by the opposite alteration in cell-cell adhesion during cancer progression^[@b19]^. Therefore, a hanging-drop assay was conducted to examine the cell-cell adhesion rate and strength of cPLA2α-knockdown and cPLA2α-overexpressing HepG2 cells. Larger aggregates were more quickly formed by HepG2 cells than by control cells, due to decreased cPLA2α expression in the former (**[Figure 1D](#Figure1){ref-type="fig"}**, left bar charts). Following 3 h of incubation, approximately 40% of cPLA2α-knockdown cells remained as large aggregates after trituration (≥ 26 cells), which was substantially higher than that of the control cells (\~15%; **[Figure 1D](#Figure1){ref-type="fig"}**, right bar charts). Conversely, cPLA2α overexpression tended to suppress cell clustering because the percentage of large aggregates (≥ 26 cells) was lower than that in control cells at different incubation time points before and after trituration (**[Figure 1E](#Figure1){ref-type="fig"}**).

Taken together, these data suggest that cPLA2α plays an important role in cell-matrix and cell-cell adhesion in HepG2 cells.

. Characterization of differentially expressed phospho-proteins in cPLA2α-knockdown and cPLA2α-overexpressing HepG2 cells {#s03.02}
-------------------------------------------------------------------------------------------------------------------------

We attempted to identify the molecular mechanism(s) underlying cPLA2α-mediated cell adhesion *via* a high-throughput phospho-protein array technique. This commercial array, which contains 1,318 site-specific and phospho-specific antibodies, enables efficient profiling of protein phosphorylation^[@b20]^. This method facilitates the detection of differentially expressed phosphorylated proteins and potential cPLA2α downstream substrates and effectors that participate in cell adhesion. Our study applied cell lysates from cPLA2α-knockdown and cPLA2α-overexpressing HepG2 cells. Log phosphorylation ratio was calculated for each screened protein (phosphorylation ratio = phosphorylated molecules/unphosphorylated molecules). For each protein, the ratio (logs) for cPLA2α-knockdown cells was plotted against the ratio (logs) for cPLA2α-overexpressing HepG2 cells (**[Figure 2A](#Figure2){ref-type="fig"}**). Fold ratios of \> 1.18 and \< 0.85 were defined as cutoff criteria. The array revealed 150 upregulated phosphorylation sites in 130 proteins, and 332 downregulated phosphorylation sites in 224 proteins in cPLA2α-knockdown cells relative to cPLA2α-overexpressing cells ( **[Figure 2A](#Figure2){ref-type="fig"}** and **[2B](#Figure2){ref-type="fig"}**). Next, a GO analysis was conducted to obtain a system-level view of these differentially expressed, phosphorylated proteins. The result showed that the targets were enriched in many biological processes, molecular functions, and cellular components (**[Figure 2C](#Figure2){ref-type="fig"}**, **[2D](#Figure2){ref-type="fig"}**, and **[2E](#Figure2){ref-type="fig"}**), indicating that cPLA2α may play various roles in different processes. These differentially expressed phosphorylated proteins were searched against the STRING database for interaction information and imported to Cytoscape for PPI network construction. A widely connected network composed of 268 proteins and 983 connections was mapped (**[Figure 2F](#Figure2){ref-type="fig"}**).

![Characterization of differentially expressed phospho-proteins in cPLA2α-knockdown and cPLA2α-overexpressing HepG2 cells. (A) For each phosphorylation site analyzed, the ratio (in logs) of phosphorylated to unphosphorylated protein in KD cells was plotted against the same ratio (in logs) in OE cells. Each phosphorylation site of which ratio was \> 1.18 or \< 0.85 was marked as a red or blue plot, respectively. Otherwise, the sites were marked as black plots. (B) The bar chart demonstrated that 150 phosphorylation sites in 130 proteins were upregulated and 332 phosphorylation sites in 224 proteins were downregulated in KD cells when compared to OE cells. (C-E) Gene oncology analysis of differentially expressed phosphoproteome in terms of biological process (C), molecular function (D) and cellular component (E). (F) The PPI network of differentially expressed phosphoproteome and their interactions were represented as nodes and edges. The node size reflected the indicated interaction degree.](cbm-16-2-377-2){#Figure2}

In summary, the phospho-antibody microarray technique indicated that changes in cPLA2α may lead to multiple phosphorylation events at specific sites.

. KEGG pathway analysis reveals the enrichment of FA pathway in differentially expressed phosphorylated proteins {#s03.03}
----------------------------------------------------------------------------------------------------------------

In order to further explore key pathways associated with these differentially expressed phosphorylated proteins, we applied the online functional annotation tool, DAVID, to identify significant pathway categories linked to cPLA2α. Our analysis indicated that these target proteins were heavily involved in various biological pathways. Based on screening criteria (*P* \< 0.01 and FDR \< 0.01), we enriched 82 KEGG pathway categories with these phospho-proteins ( **[Supplementary Table S1](#TableS1){ref-type="table"}**). The top 20 signaling pathways based on the number of relevant phosphorylated proteins are shown (**[Figure 3A](#Figure3){ref-type="fig"}**). We observed that the FA pathway, which is key to controlling cell-matrix adhesion, ranked sixth among the related pathways. This result was highly consistent with the finding that cPLA2α may enhance cell-matrix adhesion in HepG2 cells. The FA pathway was also within the top 20 pathway terms based on *P*-values (**[Figure 3B](#Figure3){ref-type="fig"}** and **[Supplementary Table S1](#TableS1){ref-type="table"}**). The online functional annotation tool, KEGG, was used to conduct the KEGG pathway mapping analysis to intuitively visualize each differentially expressed phosphorylated protein in the FA pathway (**[Figure 3C](#Figure3){ref-type="fig"}**). The map displayed concordant changes in cPLA2α and critical cell adhesion molecules, including FAK and paxillin^[@b21]^, as they were downregulated (highlighted in dark green) in cPLA2α-knockdown cells compared with those in cPLA2α-overexpressing cells.

![KEGG pathway analysis reveals the enrichment of FA pathway in differentially expressed phosphorylated proteins. (A, B) The top 20 enriched signaling pathways of differentially expressed phosphorylated proteins. X axis, KEGG term; (A) Y axis, number of phosphorylated proteins; (B) Y axis, negative logarithm (-log10) of *P*-value. The red frame (A) and rhombus (B) represented the focal adhesion pathway. (C) The KEGG pathway map of focal adhesion. Red rectangles indicated the upregulated phosphorylated proteins; dark green rectangles indicated the downregulated phosphorylated proteins; and aqua rectangles indicated the unchanged phosphorylated proteins.](cbm-16-2-377-3){#Figure3}

Considered as a whole the data indicate that components in the FA pathway play a role in cPLA2α-mediated cell-matrix adhesion.

. cPLA2α regulates the phosphorylation and colocalization of FAK and paxillin {#s03.04}
-----------------------------------------------------------------------------

The above pathway analyses denoted that a wide spectrum of phosphorylated proteins in the FA pathway were involved in cPLA2α-regulated cell-matrix adhesion. Among the proteins in the FA complex, FAK, a signaling protein which plays a pivotal role in integrin-mediated signals, initiates the first step in FAK activation, which is autophosphorylation at Tyr-397^[@b22]^. Paxillin is a FA-associated structural protein that can be phosphorylated at Tyr-118 by FAK^[@b23]^. Therefore, these two specific phosphorylation sites were selected for further analysis. Immunoblot analysis confirmed that phosphorylation of FAK (Tyr-397) and paxillin (Tyr-118) in cPLA2α-knockdown HepG2 cells was reduced (**[Figure 4A](#Figure4){ref-type="fig"}**). We further investigated the phosphorylation status of these 2 proteins in 3 other HCC cell lines, namely HLE, MHCC97H, and HCCLM3, and obtained similar results. These results demonstrated that targeted downregulation of cPLA2α significantly inhibited the expression of p-FAK and p-paxillin (**[Figure 4B](#Figure4){ref-type="fig"}**-**[4D](#Figure4){ref-type="fig"}**).

![cPLA2α regulates the phosphorylation and colocalization of FAK and paxillin. (A) Western blot analysis of cPLA2α, p-FAK (Tyr-397), FAK, p-paxillin (Tyr-118) and paxillin in cPLA2α KD/SCR, KD, OE/SCR and OE HepG2 cells. (B) Western blot analysis of cPLA2α, p-FAK (Tyr-397), FAK, p-paxillin (Tyr-118) and paxillin in cPLA2α KD/SCR, KD, OE/SCR and OE HLE cells. (C) Western blot analysis of cPLA2α, p-FAK (Tyr-397), FAK, p-paxillin (Tyr-118) and paxillin in cPLA2α KD/SCR, KD, OE/SCR and OE MHCC97H cells. (D) Western blot analysis of cPLA2α, p-FAK (Tyr-397), FAK, p-paxillin (Tyr-118) and paxillin in cPLA2α KD/SCR and KD HCCLM3 cells. (E) Immunofluorescence staining of p-FAK (Tyr-397) and paxillin as well as their colocalization in cPLA2α KD/SCR and KD HepG2 cells. (F) Immunofluorescence staining of p-FAK (Tyr-397) and paxillin as well as their colocalization in cPLA2α OE/SCR and OE HepG2 cells. Original magnifications, 400 ×.](cbm-16-2-377-4){#Figure4}

Additionally, ectopic expression of cPLA2α may lead to increased phosphorylation of FAK (Tyr-397) and paxillin (Tyr-118) in HepG2 cells (**[Figure 4A](#Figure4){ref-type="fig"}**). Similarly, phosphorylation levels of p-FAK and p-paxillin were markedly increased in HLE and MHCC97H cells with stably overexpressed cPLA2α (**[Figure 4B](#Figure4){ref-type="fig"}** and **[4C](#Figure4){ref-type="fig"}**). Considering that FAK is recruited and activated at FA sites where paxillin localizes^[@b24]^, we next examined colocalization of activated FAK (Tyr-397) and paxillin *via* immunofluorescence. The results indicated that decreased cPLA2α expression levels may hinder FAK phosphorylation at FA sites. Therefore, colocalization of p-FAK and paxillin was significantly reduced (**[Figure 4E](#Figure4){ref-type="fig"}**). Reciprocally, upregulation of cPLA2α promoted p-FAK localization at FA sites (**[Figure 4F](#Figure4){ref-type="fig"}**).

Collectively, these results suggest that cPLA2α may mediate cell-matrix adhesion through the FAK/paxillin pathway in HCC cells.

. Expression of cPLA2α and p-FAK in HCC samples and their correlation with clinical prognosis {#s03.05}
---------------------------------------------------------------------------------------------

Our study demonstrated the association between cPLA2α and p-FAK *via* *in vitro* experiments. We investigated expression patterns of cPLA2α and p-FAK in human HCCs. Eleven pairs of HCC tumors and adjacent noncancerous tissues were examined *via* Western blot analysis. The expression levels of cPLA2α and p-FAK were significantly higher in HCC tissues than in peritumoral tissues (9/11 and 10/11, respectively; **[Figure 5A](#Figure5){ref-type="fig"}**). Interestingly, overexpression of cPLA2α was accompanied by p-FAK upregulation, and even exceptional one-paired tissues (sample 3) shared the same pattern. We subsequently performed an immunohistochemical analysis of cPLA2α and p-FAK expression *via* a tissue microarray composed of primary tumor tissues from 74 HCC patients. Immunostaining indicated cytoplasmic staining for cPLA2α and nuclear and cytoplasmic staining for p-FAK (**[Figure 5B](#Figure5){ref-type="fig"}** and **[5C](#Figure5){ref-type="fig"}**). Correlation analysis confirmed correlation between cPLA2α and p-FAK (*P* \< 0.05; **[Table 1](#Table1){ref-type="table"}**). Clinicopathological analysis showed that the cPLA2α expression was significantly associated with macrovascular invasion (*P* \< 0.0001), and that p-FAK expression was significantly linked to tumor size ( *P* = 0.005), number of tumors (*P* = 0.040), and satellite nodes (*P* = 0.049); (**[Table 1](#Table1){ref-type="table"}**). In regard to prognostic value, HCC patients with high expression levels of cPLA2α or p-FAK had lower OS and DFS rates than the group with low expression levels (**[Figure 5D](#Figure5){ref-type="fig"}**, left and middle line charts). We further evaluated the combined effect of cPLA2α and p-FAK on clinical prognosis. The result showed that the cPLA2α^High^/p-FAK^High^ group had the lowest DFS rate among the 3 groups of patients (*P* = 0.031), indicating that this was the group that was most susceptible to metastasis and recurrence of HCC. However, the expression levels of cPLA2α and p-FAK had no impact on the OS rate (*P* = 0.303); (**[Figure 5D](#Figure5){ref-type="fig"}**, right line charts). Multivariate analysis revealed that cPLA2α or p-FAK alone, as well as a combination of these two, were independent prognostic factors for HCC patients (**[Table 2](#Table2){ref-type="table"}**).

![Expression of cPLA2α and p-FAK in HCC samples and their correlation with clinical prognosis. (A) Western blot analysis of cPLA2α and p-FAK expression in 11 paired cancer tissues (C) and adjacent noncancerous tissues (N). (B, C) Representative images (upper, 50 ×; lower, 200 ×) of cPLA2α and p-FAK expression by immunohistochemistry. (B) High expression of both cPLA2α and p-FAK; (C) low expression of both cPLA2α and p-FAK. (D) Kaplan-Meier analyses of overall survival (OS) and disease-free survival (DFS) rate according to cPLA2α and p-FAK expression. I, cPLA2α^Low^/p-FAK^Low^; II, cPLA2α^Low^/p-FAK^High^ and cPLA2α^High^/p-FAK^Low^; III, cPLA2α^High^/p-FAK^High^.](cbm-16-2-377-5){#Figure5}

###### 

Correlation between factors and clinicopathological characteristics in the 74 patients with HCC.

  Clinicopathological variables             Total   p-FAK^†^     　 *P*       cPLA2α^†^              　 *P*                    
  ------------------------------- --------- ------- ------------ ------------ ---------------------- ------------ ------------ ----------------------
  Age (years)                     ≤ 55      43      25 (58.1%)   18 (41.9%)   　0.409                31 (72.1%)   12 (27.9%)   　0.331
                                  \> 55     31      15(48.4%)    16 (51.6%)                          19 (61.3%)   12 (38.7%)   
  Gender                          Male      60      31(51.7%)    29 (48.3%)   　0.397                43 (71.7%)   17 (28.3%)   　0.121
                                  Female    14      9(64.3%)     5 (35.7%)                           7 (50.0%)    7 (50.0%)    
  AFP (μg/L)                      ≤ 400     47      27(57.4%)    20 (42.6%)   　0.443                33 (70.2%)   14 (29.8%)   　0.524
                                  \> 400    27      13(48.1%)    14 (51.9%)                          17 (63.0%)   10 (37.0%)   
  ALB (g/L)                       ≤ 40      25      14(56.0%)    11 (44.0%)   　0.812                17 (68.0%)   8 (32.0%)    　0.955
                                  \> 40     49      26 (53.1%)   23 (46.9%)                          33 (67.3%)   16 (32.7%)   
  Tumor size (cm)                 ≤ 5       35      25 (71.4%)   10 (28.6%)   　 **0.005**^**\***^   27 (77.1%)   8 (22.9%)    　0.098
                                  \> 5      39      15 (38.5%)   24 (61.5%)                          23 (59.0%)   16 (41.0%)   
  Tumor number                    ≤ 1       58      35 (60.3%)   23(39.7%)    　 **0.040**^**\***^   41 (70.7%)   17 (29.3%)   　0.278
                                  \> 1      16      5 (31.3%)    11(68.7%)                           9 (56.3%)    7 (43.7%)    
  HBV                             Absent    21      9 (42.9%)    12 (57.1%)   　0.227                17 (81.0%)   4 (19.0%)    　0.124
                                  Present   53      31 (58.5%)   22 (41.5%)                          33 (62.3%)   20 (37.7%)   
  HCV                             Absent    68      39 (57.4%)   29 (42.6%)   　0.057                47 (69.1%)   21 (30.9%)   　0.341
                                  Present   6       1 (16.7%)    5 (83.3%)                           3(50.0%)     3 (50.0%)    
  Liver cirrhosis                 Absent    38      18 (47.4%)   20 (52.6%)   　0.239                23 (60.5%)   15 (39.5%)   　0.187
                                  Present   36      22 (61.1%)   14 (38.9%)                          27 (75.0%)   9 (25.0%)    
  Tumor encapsulation             Absent    70      37 (52.9%)   33 (47.1%)   　0.391                46 (65.7%)   24 (34.3%)   　0.157
                                  Present   4       3 (75.0%)    1 (25.0%)                           4 (100%)     0 (0%)       
  Tumor thrombus                  Absent    26      14 (53.8%)   12 (46.2%)   　0.979                18 (69.2%)   8 (30.8%)    　0.823
                                  Present   48      26 (54.2%)   22 (45.8%)                          32 (66.7%)   16 (33.3%)   
  Satellite node                  Absent    48      30 (62.5%)   18 (37.5%)   　 **0.049**^**\***^   33 (68.8%)   15 (31.2%)   　0.769
                                  Present   26      10 (38.5%)   16 (61.5%)                          17 (65.4%)   9 (34.6%)    
  MVI                             Absent    70      37 (52.9%)   33 (47.1%)   　0.391                47 (67.1%)   23 (32.9%)   　0.746
                                  Present   4       3 (75.0%)    1 (25.0%)                           3 (75.0%)    1 (25.0%)    
  MAVI                            Absent    68      37 (54.4%)   31 (45.6%)   　0.836                50 (73.5%)   18 (26.5%)   　 **0.000**^**\***^
                                  Present   6       3 (50.0%)    3 (50.0%)                           0 (0%)       6 (100%)     
  p-FAK                           Low       40                                                       31 (77.5%)   9 (22.5%)    　 **0.049**^**\***^
                                  High      34                                                       19 (55.9%)   15 (44.1%)   
  cPLA2α                          Low       50      31 (62.0%)   19 (38.0%)   　 **0.049**^**\***^                             
                                  High      24      9 (37.5%)    15 (62.5%)                                                    

###### 

Univariate and multivariate analysis of prognostic factors associated with OS and DFS in 74 patients with HCC.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables               Number   Univariate analysis                       Multivariate analysis                       Univariate analysis                       Multivariate analysis                             
  ----------------------- -------- --------------------- ------------------- ----------------------- ------------------- --------------------- ------------------- ----------------------- ------------------- -- -- --
  Age (years)\            43/31    65.1/58.1             0.665                                                                                                     51.2/35.5               0.290                     
  (≤ 55/\> 55)                                                                                                                                                                                                       

  Gender (male/female)    60/14    60.0/71.4             0.503                                                           46.7/35.7             0.369                                                                 

  AFP (μg/L)\             47/27    66.0/55.6             0.343                                                           48.9/37.0             0.249                                                                 
  (≤ 400/\> 400)                                                                                                                                                                                                     

  ALB (g/L)\              25/49    64.0/61.2             0.926                                                           44.0/44.9             0.808                                                                 
  (≤ 40/\> 40)                                                                                                                                                                                                       

  Tumor size\             35/39    71.4/53.8             0.116                                                           57.1/33.3             0.055                                                                 
  (cm) (≤ 5/\> 5)                                                                                                                                                                                                    

  Tumor number\           58/16    67.2/43.8             0.088                                                           46.6/37.5             0.428                                                                 
  (≤ 1/\> 1)                                                                                                                                                                                                         

  HBV (N/Y)               21/53    57.1/64.2             0.643                                                           42.9/45.3             0.869                                                                 

  HCV (N/Y)               68/6     66.2/16.7             **0.009**^**\***^   1.81\                   0.256               47.1/16.7             0.123                                                                 
                                                                             (0.65, 5.02)                                                                                                                            

  Liver cirrhosis (N/Y)   38/36    55.3/69.4             0.310                                                           34.2/55.6             0.112                                                                 

  Tumor\                  70/4     60.0/0                0.155                                                           41.4/0                0.062                                                                 
  encapsulation (N/Y)                                                                                                                                                                                                

  Tumor\                  26/48    61.5/62.5             0.793                                                           50.0/41.7             0.626                                                                 
  thrombus (N/Y)                                                                                                                                                                                                     

  Satellite\              48/26    66.7/53.8             0.179                                                           45.8/42.3             0.670                                                                 
  nodule (N/Y)                                                                                                                                                                                                       

  MVI (N/Y)               70/4     62.9/50.0             0.491                                                           44.3/50.0             0.820                                                                 

  MAVI (N/Y)              68/6     66.2/16.7             **0.000**^**\***^   1.93\                   0.226               48.5/0                0.000^**\***^       1.79\                   0.239                     
                                                                             (0.67, 5.61)                                                                          (0.68, 4.71)                                      

  p-FAK (L/H)             40/34    82.5/38.2             **0.000**^**\***^   3.34\                   **0.008**^**\***^   65.0/20.6             **0.000**^**\***^   2.28\                   **0.014**^**\***^         
                                                                             (1.37, 8.18)                                                                          (1.18, 4.38)                                      

  cPLA2α (L/H)            50/24    78.0/29.2             **0.000**^**\***^   4.20\                   **0.002**^**\***^   60.0/12.5             **0.000**^**\***^   3.97\                   **0.000**^**\***^         
                                                                             (1.68, 10.46)                                                                         (1.97, 8.01)                                      

  p-FAK +\                                               **0.000**^**\***^   1.59\                   0.303                                     **0.000**^**\***^   2.05\                   **0.031**^**\***^         
  cPLA2α†                                                                    (0.66, 3.83)                                                                          (1.07, 3.93)                                      

  I                       31       90.3                                                                                  77.4                                                                                        

  II                      28       57.1                                                                                  28.6                                                                                        

  III                     15       13.3                                                                                  6.7                                                                                         
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Thus, we concluded that, apart from cPLA2α expression alone, p-FAK and cPLA2α expressions combined with p-FAK were also associated with poor prognosis in HCC patients.

. Discussion {#s04}
============

In mammalian cells, cPLA2α is a widely expressed phospholipase. Activation of cPLA2α is calcium dependent. In normal physiological processes and pathophysiological reactions, its regulatory functions are mainly dependent on its glycerophospholipid hydrolysates, AA, and lysophospholipids^[@b6],\ [@b25]^. Reportedly, metabolites of both these hydrolysates are associated with inflammation, carcinogenesis, and cancer progression^[@b7],\ [@b26]^. Previously, our studies confirmed the promalignant role of cPLA2α in breast cancer and HCC^[@b8],\ [@b9]^. In addition to the alteration of migratory, invasive, and metastatic abilities, attachment to the plastic surface of cell culture dishes changed with the downregulation or upregulation of cPLA2α expression. We performed a cell adhesion and detachment assay to ascertain whether knocking down cPLA2α would significantly weaken cell-matrix adhesion in HepG2 cells. By contrast, heterotypic adhesion was enhanced when cPLA2α expression was increased. We also observed tighter connections between cancer cells in cPLA2α-knockdown HepG2 cells than in control cells and reduced cell-cell adhesion in cPLA2α-overexpressing HepG2 cells. These results were consistent with the role played by cPLA2α in promoting the EMT process, which allows epithelial cancer cells to acquire a mesenchymal phenotype; these cells are then able to migrate and metastasize easily^[@b8],\ [@b27]^. To our knowledge, our research is among the first studies to investigate the effect of cPLA2α on cell adhesion in HCC.

Protein arrays based on antigen-antibody reaction (antibody arrays) is a form a high-throughput technology used for proteome profiling. This technology effectively interprets biological functions of candidate proteins based on known identities of previously profiled proteins^[@b18],\ [@b28]^. We used the Phospho Explorer Antibody Array, an ELISA-based antibody array that detects protein phosphorylation on a large scale^[@b29]^. This phospho-antibody array has been widely applied to improve our understanding of cancer pathogenesis. For example, Jiang et al.^[@b30]^, conducted a quantitative phosphoproteomic analysis using this array, to comprehensively explore the role of SSBP1 in breast cancer metastasis. We identified multiple proteins, the phosphorylation status of which were modulated by cPLA2α in HCC cells. KEGG pathway analysis of these differentiated phospho-proteins revealed that the PI3K/Akt, MAPK, and Ras signaling pathways were within the top 5 related pathways (**[Supplementary Table S1](#TableS1){ref-type="table"}**). The dysregulation of these pathways has been widely characterized and well recognized in cancer development and progression^[@b31],\ [@b32]^. These results are consistent with revealed functions of cPLA2α in HCC^[@b8],\ [@b33]^.

The FA pathway was the sixth top relevant pathway with 46 associated proteins. Such significant enrichment precisely confirmed our present findings that cPLA2α may promote cell-matrix adhesion in HCC cells. This pathway regulates dynamic interaction between cells and the ECM through FA formation and disassembly. Such interaction is crucial for cancer cell migration and metastasis^[@b34]^. FAK is a key regulator of integrin-mediated adhesion. FAK can be auto-phosphorylated at Tyr-397 upon recruitment of this kinase to FA sites following the binding of the transmembrane integrin receptor to ECM. An activated FAK provides both signal transduction and scaffolding functions^[@b19],\ [@b35]^. Paxillin is an important FA-associated cytoskeletal adaptor protein that provides a docking site for FAK. In turn, FAK can phosphorylate paxillin at Tyr-118 to regulate its function^[@b24]^. Phosphorylation of both proteins is required for FA formation, cell motility, and metastasis^[@b36]^. The current study indicated that cPLA2α may stimulate the phosphorylation of FAK and paxillin at Tyr-397 and Tyr-118, respectively. Reduced p-FAK colocalization with the FA marker paxillin in cPLA2α-knockdown HepG2 cells strongly decreased the activity of the integrin-mediated FA pathway^[@b37]^, whereas increased colocalization was observed in cPLA2α-overexpressing HepG2 cells. These observations suggested that cPLA2α may promote cell-matrix adhesion through activation of the FAK/paxillin pathway in HCC. To the best of our knowledge, ours is the first study to investigate the mechanism underlying cell-matrix adhesion regulated by cPLA2α in HCC. The positive association between cPLA2α and the FAK/paxillin pathway may provide a possible explanation for the cancer-promoting role of cPLA2α in HCC. However, further research is needed to confirm this finding.

Here, Western blot and immunohistochemistry related techniques were utilized to investigate the association between cPLA2α expression and p-FAK expression in 11 paired clinical tissue samples and another cohort of 74 HCC patients, respectively. Similar to our previous results, our present findings showed that cPLA2α expression was higher in primary HCC tissues than in the adjacent nontumor tissues. This study was the first to reveal that cPLA2α overexpression was accompanied by an increase in p-FAK levels. This result was consistent with *in vitro* experiments showing that p-FAK (Tyr-397) expression could be accelerated by cPLA2α upregulation. Furthermore, we estimated the prognostic role of cPLA2α and p-FAK in HCC patients. We divided the 74 patients into 3 subclasses, cPLA2α^High^/p-FAK^High^, cPLA2α^High^/p-FAK^Low^ or cPLA2α^Low^/p-FAK^High^, and cPLA2α^Low^/p-FAK^Low^, based on expression levels. Among these 3 groups, the group with higher expression levels of cPLA2α and p-FAK exhibited the poorest disease-free survival outcomes. Thus, cPLA2α^High^/p-FAK^High^ was more sensitive than cPLA2α^High^ or p-FAK^High^ alone in predicting the prognosis of HCC patients.

. Conclusions {#s05}
=============

Overall, the current study showed that cPLA2α may enhance cell-matrix adhesion *via* the FAK/paxillin pathway in HCC. This function of cPLA2α may be essential for its prometastatic role in HCC. However, further in-depth research may be required to verify this notion. In addition, the expression of cPLA2α or p-FAK alone, or the co-index (cPLA2α/p-FAK), may serve as prognostic factors for HCC patients. These findings could contribute to the development of new treatment strategies for HCC.
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Cell lines and cell culture {#sm01.01}
---------------------------

MHCC97H and HCCLM3 cells were bought from the Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China. HepG2 cells were obtained from American Type Culture Collection (ATCC; Manassas, VA, USA). HLE cells from the Health Science Research Resources Bank (Osaka, Japan) were also utilized. MHCC97H, HCCLM3 and HLE cells were cultured in Dulbecco's modified Eagle's medium (Gibco, Carlsbad, CA, USA), and HepG2 cells were incubated in Eagle's minimum essential medium (Gibco), containing 10% fetal bovine serum (FBS; HyClone Laboratories Inc., Novato, CA, USA) and 1% penicillin-streptomycin solution (PS; Hyclone Laboratories Inc.) at 37 °C under a 5% CO~2~ atmosphere.

Cell transfection {#sm01.02}
-----------------

The lentiviral vectors carrying cPLA2α shRNA, cPLA2α, and their respective scrambled controls (Genechem Co., Shanghai, China) were separately transfected into cells by using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) in accordance with the manufacturer's instructions. Stably transfected clones were selected using a puromycin (Gibco)-containing medium. The transfection efficiency was validated through western blot assay.

Western blot assay {#sm01.03}
------------------

The cell lysates were separated through sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The separated products were transferred to polyvinylidene difluoride membranes (Immobilon-P, Millipore, Billerica, MA, USA). The following primary antibodies were used: cPLA2α (1:500, GTX110218) (GeneTex, Irvine, TX, USA); FAK (1:100, H-1: sc-1688), paxillin (1:200, D-9: sc-365174), and GAPDH (1:1000, 0411: sc-47724) (Santa Cruz Biotechnology, CA, USA); p-FAK (1:1000, ET1610-34) (Hangzhou HuaAn Biotechnology Co., Zhejiang, China); and p-paxillin (1:500, 2541) (Cell Signaling Technologies, Danvers, MA, USA).

Cell adhesion assay {#sm01.04}
-------------------

In brief, 2 × 10^5^ cells/well were added to a 12-well plate containing glass coverslips pretreated with 10 μg/mL fibronectin (R&D Systems Inc., Minneapolis, MN, USA). After 5, 15, and 30 min of incubation, the cells were gently washed twice with cold PBS and then fixed with 4% paraformaldehyde for 5-10 min. Five random fields (200 ×) were chosen to count the number of attached cells. All the samples were tested in triplicate and the data are expressed as the mean ± S.D.

Cell detachment assay {#sm01.05}
---------------------

The cells were seeded at 1 × 10^5^ cells/well in a 12-well plate, which was pretreated with 1.2 mg/mL Matrigel (BD Biosciences, Franklin Lakes, NJ, USA). After 48 h, the cells were washed with PBS and then trypsinized with 0.25% trypsin (Hyclone Laboratories Inc.) at 20 °C with gentle agitation. The number of detached cells was counted at different time points, and the total number of cells/well was determined after trypsinization was completed. One well was used for each time point, and each experiment was independently performed at least three times.

Hanging-drop adhesion assay {#sm01.06}
---------------------------

Briefly, a 30 μL drop of the cells (1 × 10^5^/mL) in culture medium was placed on the inner surface of a 35 mm dish lid. The lid was placed on a dish to ensure that the drops with suspended cells hung from the lid. Approximately 2 mL of the medium was added to the dish to prevent evaporation. Then, the dishes were incubated at 37 °C in a 5% CO~2~ atmosphere. The lid was then inverted, and cell trituration was performed with a 20 μL pipette tip for 20 times. Three random fields of each drop were photographed, and \> 1000 cells were counted per experiment.

Immunofluorescence {#sm01.07}
------------------

Approximately 4 × 10^4^/well cells were seeded in a 12-well plate containing sterile coverslips. After the cells attached, they were fixed with 4% paraformaldehyde, permeabilized with 0.2% Triton X-100 in PBS, and incubated with the primary antibodies p-FAK (1:50) (Hangzhou HuaAn Biotechnology Co.) and paxillin (1:10) (Santa Cruz Biotechnology) overnight at 4 °C. The secondary antibodies used in this study included Alexa Fluor 488-conjugated and 594-conjugated antibodies (Invitrogen, Carlsbad, CA, USA). Cell nuclei were counterstained with diamidino phenylindole (Solarbio, Beijing, China). The fluorescence intensity of the cells was visualized under a fluorescence microscope (Zeiss, Oberkochen, BW, Germany).

Immunohistochemistry {#sm01.08}
--------------------

Paraffin-embedded tissue slides were deparaffinized and rehydrated. Microwave antigen retrieval was conducted using 10 mM citrate (pH = 6.0) (Zhongshan Golden Bridge Biotechnology, Beijing, China), and the primary antibodies against cPLA2α (1:80, N-216: sc-438) (Santa Cruz Biotechnology) and p-FAK (1:25) (Hangzhou HuaAn Biotechnology Co.) were applied to the slides and incubated at 4 °C overnight. Next, the tissues were incubated with the secondary anti-rabbit antibody (PV-6002) (Zhongshan Golden Bridge Biotechnology) for 1 h at 37 °C, stained with DAB (Zhongshan Golden Bridge Biotechnology), and counter-stained with 10% Mayer\'s hematoxylin (Solarbio).

The staining intensity of the cPLA2α expression was evaluated as follows: 0, no staining; 1, weak staining; and 2, strong staining. The percentage of positive cells was scored as follows: 0, \< 10% positive cells; 1, 10%--40% positive cells; 2, 40%--70% positive cells; and 3, 70%--100% positive cells. The sum of the two scores was graded as low (score = 0--3) or high (score = 4--5). For p-FAK, the criteria of intensity evaluation were as follows: 0, negative staining; 1, weak staining; 2, moderate staining; and 3, strong staining. The extent of positive cells was scored as follows: 0, \< 5%; 1, 5%--25%; 2, 26%--50%; 3, 51%--75%; and 4, \> 75%. The sum of the two scores was classified as low (score = 0--3) or high (score = 4--7).

###### 

KEGG pathway enrichment of differentially expressed phosphorylated proteins by DAVID

  **Pathway term**                                                      **Count†**   ***P*-value**   **Swiss prot**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           **FDR**
  --------------------------------------------------------------------- ------------ --------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------
  hsa05200:pathways in cancer                                           73           1.09E-32        P24385, P42224, Q13043, Q92769, P16234, Q01970, P10398, P84022, Q12778, P42229, P11274, Q00987, P16885, P38936, P17612, P55211, P10415, P15056, P06400, P05556, P49841, Q92934, P25963, P24864, P00519, P05771, P63000, P04637, P08069, P05412, Q07817, P08238, P98170, Q04206, P55957, P60484, P46527, P07333, P11362, P08581, O14920, P17252, Q02750, P35222, O75030, O15111, Q13547, P10275, P09619, P51692, P04626, P31751, Q13158, P01106, P42345, P37231, P01100, Q9Y6K9, P46108, P07949, P23458, P19174, P19838, P24941, O15392, P10721, P04049, Q15796, Q05397, P42574, P00533, P40763, P31749   1.36E-29
  hsa04151:PI3K-Akt signaling pathway                                   68           6.55E-32        P24385, P16234, P49815, P62753, P35568, O15530, Q00987, P38936, P55211, P10415, O43521, Q16543, P24394, P05556, P49841, Q92934, P24864, P17948, P05106, O43524, P63000, P16220, P04637, P08069, Q07817, P35968, P08238, Q04206, P26951, P01589, P60484, Q9UBS0, P46527, Q15831, P07333, P23443, P11362, P08581, O14920, P17252, Q02750, O15111, O60674, P38398, P09619, P29474, P31751, P43405, P01106, P42345, P30281, Q9Y6K9, P63104, Q13131, P23458, P18848, Q13541, P16144, P15336, P19838, P24941, P06730, P10721, P04049, P19235, Q05397, P00533, P31749                                           8.20E-29
  hsa04010:MAPK signaling pathway                                       55           1.69E-27        Q13043, P19419, P16234, P28562, O43318, Q99683, P30305, P17612, P15056, Q13153, Q9BUB5, P21333, P05771, P47712, P63000, P04637, Q15418, P05412, Q01201, P16949, Q04206, P45985, Q16539, P04792, P49407, P11362, O14920, P17252, Q02750, O15111, P09619, P31751, P17535, P01106, Q12968, P11831, P01100, P46108, Q9Y6K9, P46734, P41279, P10636, P18848, Q13972, P15336, P19838, Q13177, P04049, Q16620, Q06413, P42574, O75582, O14733, P00533, P31749                                                                                                                                                   2.12E-24
  hsa05205:proteoglycans in cancer                                      50           5.08E-28        P24385, P12931, P19419, P62753, P10398, Q03135, P62136, P15311, Q00987, O15530, P16885, Q9UQM7, P38936, P17612, P15056, P05556, Q13153, P21333, P17844, P05771, P05106, P63000, P04637, P08069, P35968, Q16539, Q9UBS0, P23443, P11362, P08581, P17252, Q02750, P35222, P04626, Q06124, P31751, P01106, P42345, P19174, Q13480, P04049, P03372, P49023, Q05397, P21860, P42574, P00533, P31749, P40763, Q14247                                                                                                                                                                                           6.36E-25
  hsa04014:Ras signaling pathway                                        49           1.76E-24        Q13043, P07333, P19419, P11362, P17252, P08581, O14920, Q05586, P16234, Q02750, O15111, P62158, P42684, P09619, P43403, P16885, P31751, Q06124, P17612, O75914, P98177, Q9Y6K9, P29353, Q04864, Q9UQC2, Q13153, Q92934, Q13972, P19174, P17948, P05771, P19838, Q13177, P00519, O43561, P47712, P63000, P10721, Q13480, P04049, P08069, Q13393, Q07817, P35968, Q04206, Q8IVT5, Q13224, P00533, P31749                                                                                                                                                                                                   2.20E-21
  hsa04510:focal adhesion                                               46           1.70E-23        P24385, P18206, P12931, P19419, P17252, P08581, P16234, Q02750, P35222, Q03135, P62136, P56945, O15530, P09619, P04626, P31751, P30281, O75914, P46108, P29353, P10415, P15056, P05556, Q13153, Q92934, P49841, Q13972, P52735, P21333, P16144, P17948, P05771, Q13177, P05106, P63000, P04049, P08069, P05412, P35968, P50552, Q05397, P49023, P98170, P60484, P00533, P31749                                                                                                                                                                                                                           2.13E-20
  hsa05161:hepatitis B                                                  45           1.88E-29        P24385, P42224, P12931, Q14289, P19419, P17252, O14920, Q02750, P42226, P42229, O15111, P51692, P31751, Q13158, P38936, P01106, Q12968, P01100, Q9Y6K9, P55211, P10415, P63104, P06400, P23458, P18848, Q92934, P25963, P24864, P15336, P05771, P19838, P24941, P16220, P04637, O15392, P04049, P05412, P52630, Q04206, P45985, P42574, P60484, P46527, P31749, P40763                                                                                                                                                                                                                                   2.36E-26
  hsa05169:Epstein-Barr virus infection                                 44           4.09E-23        Q92769, O14920, P67870, O15111, Q13547, O43318, Q00987, P16885, P56524, Q13651, P43405, P31751, P38936, P01106, P17612, O00221, Q9Y6K9, P46734, P10415, P63104, P07948, P06400, P23458, Q15653, P49841, P05362, P25963, P19525, P15336, P19174, P19838, P24941, P04637, P05412, Q01201, Q9UQL6, Q04206, P45985, Q16539, O14733, P04792, P40763, P46527, P31749                                                                                                                                                                                                                                           5.11E-20
  hsa05166:HTLV-I infection                                             42           3.86E-16        P24385, P06239, P19419, O14920, P16234, P84022, P35222, P42229, O15111, P09619, P51692, P31751, P38936, P01106, P17612, P11831, Q12968, P30281, P01100, Q9Y6K9, P06400, O14757, P18846, P23458, P18848, P49841, P05362, P25963, P15336, O96017, P19838, P16220, P04637, P05412, Q07817, Q15796, Q01201, Q04206, P98170, P45985, P01589, P31749                                                                                                                                                                                                                                                           4.22E-13
  hsa05203:viral carcinogenesis                                         41           4.83E-19        P24385, P12931, Q92769, Q9UBN7, O15379, P42229, Q13547, Q00987, P56524, P51692, P43405, P38936, P17612, P11831, P30281, Q9Y6K9, P63104, P07948, Q04864, P06400, O14757, P23458, P18848, Q92934, P25963, P24864, P19525, P15336, P19838, P24941, P16220, P63000, P04637, P05412, P49023, Q9UQL6, Q9BY41, Q04206, P42574, P46527, P40763                                                                                                                                                                                                                                                                   6.04E-16
  hsa05206:microRNAs in cancer                                          41           7.89E-14        P24385, P17252, O14920, P08581, P16234, Q02750, P35568, Q02156, P15311, Q00987, P38398, P09619, P16885, P04626, P29966, P30305, P30304, P38936, P01106, P42345, P46108, P30307, P29353, P10415, O43521, P24864, P19174, P05771, P19838, P00519, P05106, P04637, P04049, P16949, P42574, P21860, O75582, P60484, P00533, P46527, P40763                                                                                                                                                                                                                                                                   9.86E-11
  hsa04012:ErbB signaling pathway                                       39           2.16E-32        P12931, P23443, P19419, P17252, Q02750, P10398, P42229, P42684, P16885, P51692, P04626, Q9UQM7, P31751, P38936, P01106, P42345, O75914, P46108, P29353, P15056, Q13153, P49841, Q92934, P19174, Q13541, P05771, P00519, Q13177, Q13480, P04049, P05412, Q05397, P45985, P21860, P00533, O14733, Q9UBS0, P46527, P31749                                                                                                                                                                                                                                                                                   2.70E-29
  hsa05215:prostate cancer                                              39           3.68E-32        P24385, P11362, O14920, P16234, Q02750, P10398, Q12778, P35222, O15111, P10275, Q00987, O15530, P09619, P04626, P31751, P38936, P42345, Q9Y6K9, P55211, P10415, P15056, P06400, P18848, P49841, Q92934, P25963, P24864, P19838, P24941, P16220, P04637, P04049, P08069, P08238, Q04206, P60484, P00533, P46527, P31749                                                                                                                                                                                                                                                                                   4.60E-29
  hsa04722:neurotrophin signaling pathway                               39           3.04E-26        P52565, O14920, Q02750, P35568, P62158, O15530, Q99683, P16885, Q06124, Q9UQM7, P31751, O00221, P46108, P29353, P10415, P15056, P18848, Q15653, P49841, Q92934, P25963, P19174, Q05655, P19838, P00519, Q16566, P63000, O43524, P04637, Q13480, Q15418, P04049, P05412, Q16620, Q04206, O75582, Q16539, O14733, P31749                                                                                                                                                                                                                                                                                   3.80E-23
  hsa04015:Rap1 signaling pathway                                       38           4.93E-16        P12931, P07333, P11362, P17252, P08581, Q05586, P16234, Q01970, Q02750, P35222, P62158, Q13094, P56945, Q15139, P09619, O60716, P31751, P46108, P46734, P15056, P05556, P19174, P17948, P05771, O43561, P05106, P63000, P10721, P04049, P08069, P35968, P50552, Q9BZL6, Q13224, Q16539, P00533, P31749, Q05513                                                                                                                                                                                                                                                                                           5.55E-13
  hsa04062:chemokine signaling pathway                                  37           4.36E-17        P42224, P12931, Q14289, O14920, Q01970, Q02750, O15111, P56945, O60674, P51692, P31751, P08631, P17612, P46108, Q9Y6K9, P29353, P25098, P15056, P07948, Q13153, Q15653, P49841, P25963, P52735, Q05655, P19838, P63000, O43524, P04049, Q05397, P49023, P52630, Q04206, P49407, P31749, P40763, Q05513                                                                                                                                                                                                                                                                                                   5.45E-14
  hsa04380:osteoclast differentiation                                   36           1.81E-21        P17275, P06239, P42224, P07333, O14920, Q02750, Q06187, O75030, O15111, O43318, Q13094, P16885, P43405, P31751, P17535, P37231, P01100, Q9Y6K9, P15260, Q9UQC2, P23458, P25963, P19838, P05106, Q16566, Q8WV28, P16220, P63000, P05412, Q01201, P52630, Q04206, Q16539, P53539, O14733, P31749                                                                                                                                                                                                                                                                                                           2.27E-18
  hsa04660:T cell receptor signaling pathway                            33           6.49E-22        P20963, P06239, P01730, O14920, Q02750, O15111, O43318, Q13094, O15530, P43403, P31751, Q12968, O75914, P01100, O00221, Q9Y6K9, P41279, Q13153, Q15653, P49841, P25963, P52735, P19174, P19838, Q13177, O43561, P04049, P05412, Q04759, Q04206, Q16539, O14733, P31749                                                                                                                                                                                                                                                                                                                                   8.12E-19
  hsa05220:chronic myeloid leukemia                                     31           5.91E-25        P24385, Q92769, O14920, Q02750, P10398, P42229, O15111, Q13547, P11274, Q00987, P51692, Q06124, P31751, P38936, P01106, Q9Y6K9, P46108, P29353, P15056, P06400, Q9UQC2, Q92934, P25963, P19838, P00519, P04637, P04049, Q07817, Q04206, P46527, P31749                                                                                                                                                                                                                                                                                                                                                   7.40E-22
  hsa04068:FoxO signaling pathway                                       31           3.33E-16        P24385, Q15831, Q13043, O14920, Q02750, P04040, P10398, P35568, Q12778, P84022, O15111, Q00987, O15530, P31751, P38936, P98177, P15056, Q13131, O43521, P24941, O43524, P14635, P04049, P08069, Q15796, P60484, Q16539, P00533, P40763, P46527, P31749                                                                                                                                                                                                                                                                                                                                                   4.22E-13
  hsa04910:insulin signaling pathway                                    31           8.97E-16        P23443, P19419, O14920, P49815, Q02750, P62753, P10398, P35568, Q12778, P62136, P62158, P36956, O15530, P31751, P17612, P42345, P46108, P29353, P15056, Q13131, P49841, Q92934, Q9BUB5, Q13541, Q05469, P06730, P04049, Q13085, Q9UBS0, P31749, Q05513                                                                                                                                                                                                                                                                                                                                                   1.11E-12
  hsa04919:thyroid hormone signaling pathway                            30           2.67E-17        P24385, P42224, P12931, Q92769, P17252, O15379, P49815, Q01970, Q02750, Q12778, P35222, Q13547, O15530, Q00987, P16885, P31751, P01106, P17612, P42345, P55211, P49841, Q92934, P19174, P05771, P05106, P04637, P04049, P03372, P31749, Q15648                                                                                                                                                                                                                                                                                                                                                           3.34E-14
  hsa05162:measles                                                      28           1.60E-13        P24385, P42224, P67870, P42229, O15111, O43318, O60674, P51692, P31751, P30281, P15260, P23458, P49841, Q15653, P25963, P24864, P19525, P24941, P19838, Q99704, P04637, Q04759, P52630, Q04206, P01589, P40763, P46527, P31749                                                                                                                                                                                                                                                                                                                                                                           2.00E-10
  hsa04666:Fc gamma R-mediated phagocytosis                             27           6.21E-18        P23443, P17252, Q02750, P23528, Q02156, P16885, P53667, P43405, P31751, P29966, P08631, P46108, P07948, Q9UQC2, Q13153, P52735, P19174, P05771, Q05655, O43561, P63000, P04049, Q92558, Q13393, P50552, Q9UBS0, P31749                                                                                                                                                                                                                                                                                                                                                                                   7.77E-15
  hsa04066:HIF-1 signaling pathway                                      27           4.22E-16        P23443, P17252, Q02750, P62753, P16885, P04626, P29474, Q9UQM7, P31751, P38936, P42345, P10415, P15260, Q9BUB5, Q13541, P19174, P17948, P05771, P19838, P06730, P08069, Q04206, P00533, Q9UBS0, P46527, P31749, P40763                                                                                                                                                                                                                                                                                                                                                                                   5.55E-13
  hsa05164:influenza A                                                  27           6.37E-10        P29466, P42224, P17252, O14920, Q02750, O60674, P31751, P46734, P55211, P15260, P23458, P49841, Q15653, P05362, P25963, P19525, P15336, P05771, P19838, P04049, P05412, P52630, Q04206, P45985, Q16539, O14733, P31749                                                                                                                                                                                                                                                                                                                                                                                   7.97E-07
  hsa05034:alcoholism                                                   27           9.33E-10        Q92769, Q9UBN7, O15379, Q05586, Q02750, Q71DI3, P10398, P62158, P62136, Q13547, P84243, P07101, P56524, P29353, P15056, P16104, P18848, P15336, Q16566, P16220, P04049, Q16620, Q9UQL6, Q9BY41, P68431, Q13224, P53539                                                                                                                                                                                                                                                                                                                                                                                   1.17E-06
  hsa04024:cAMP signaling pathway                                       27           1.07E-08        Q05586, Q02750, P42262, P62158, P62136, Q9UQM7, P31751, P17612, P01100, P15056, Q13153, Q92934, P25963, P52735, P19838, Q16566, Q92736, Q05469, P63000, P16220, P42261, P04049, Q13393, P05412, Q04206, Q13224, P31749                                                                                                                                                                                                                                                                                                                                                                                   1.34E-05
  hsa04810:regulation of actin cytoskeleton                             27           4.08E-08        P18206, P12931, P11362, P16234, Q02750, P10398, P23528, P62136, P56945, P15311, P09619, P53667, O75914, P46108, P15056, P05556, Q13153, P52735, P16144, Q13177, P05106, P63000, P04049, Q92558, Q05397, P49023, P00533                                                                                                                                                                                                                                                                                                                                                                                   5.10E-05
  hsa04668:TNF signaling pathway                                        26           3.48E-14        P17275, O14920, Q02750, O15111, O43318, Q99683, Q13158, P31751, P01100, P46734, Q9Y6K9, P41279, P18848, P05362, P25963, P15336, P19838, P16220, P05412, Q04206, P45985, P42574, Q16539, O75582, O14733, P31749                                                                                                                                                                                                                                                                                                                                                                                           4.35E-11
  hsa04931:insulin resistance                                           26           5.53E-14        P23443, O14920, Q12778, P35568, Q02156, P62136, P36956, O15530, P29474, Q06124, P31751, P42345, Q13131, P49841, P25963, Q05655, P19838, P16220, Q15418, Q04759, Q04206, P60484, Q9UBS0, P31749, P40763, Q05513                                                                                                                                                                                                                                                                                                                                                                                           6.92E-11
  hsa05145:toxoplasmosis                                                26           4.81E-13        P42224, O14920, O15111, O43318, O60674, O15530, Q13651, P31751, P46734, Q9Y6K9, P55211, P10415, P15260, P23458, P05556, Q15653, Q92934, P25963, P19838, Q07817, Q04206, P98170, P42574, Q16539, P40763, P31749                                                                                                                                                                                                                                                                                                                                                                                           6.02E-10
  hsa04110:cell cycle                                                   26           1.58E-12        P06400, P24385, O14757, Q92769, P49841, P24864, O96017, P00519, P24941, P84022, P50613, P78527, P04637, Q13547, P14635, Q15796, Q00987, Q14683, P30305, P30304, P01106, P38936, P30281, P30307, P46527, P63104                                                                                                                                                                                                                                                                                                                                                                                           1.97E-09
  hsa05202:transcriptional misregulation in cancer                      26           1.52E-09        P07333, Q92769, P08581, Q15797, Q71DI3, Q12778, Q13547, P84243, Q00987, P38936, P01106, P37231, Q04864, P18846, P17948, P17844, P19838, P04637, P08069, Q07817, Q06413, Q05397, P68431, Q04206, P08047, P46527                                                                                                                                                                                                                                                                                                                                                                                           1.90E-06
  hsa05212:pancreatic cancer                                            25           1.12E-18        P06400, P24385, P42224, P23458, Q92934, O14920, Q02750, P19838, P10398, P84022, O15111, P63000, P04637, P04049, Q07817, Q15796, P04626, P31751, Q04206, P00533, Q9Y6K9, P55211, P31749, P40763, P15056                                                                                                                                                                                                                                                                                                                                                                                                   1.41E-15
  hsa04921:oxytocin signaling pathway                                   25           2.15E-09        Q13131, P24385, P12931, P19419, P17252, Q01970, Q02750, P05771, Q16566, Q92736, P47712, P62158, P62136, P04049, P05412, Q14012, Q06413, P29474, Q9UQM7, O00418, P38936, Q12968, P17612, P00533, P01100                                                                                                                                                                                                                                                                                                                                                                                                   2.69E-06
  hsa05214:glioma                                                       24           1.85E-17        P06400, P24385, P17252, P16234, P19174, Q02750, P05771, P10398, P62158, P04637, P08069, P04049, Q00987, P09619, P16885, P31751, Q9UQM7, P38936, P42345, P60484, P00533, P31749, P29353, P15056                                                                                                                                                                                                                                                                                                                                                                                                           2.31E-14
  hsa04650:natural killer cell mediated cytotoxicity                    24           5.50E-11        P15260, P20963, P06239, Q13153, Q14289, P05362, P17252, P52735, P19174, Q02750, P05771, P10398, O43561, P63000, P04049, Q13094, P43403, P16885, P43405, Q06124, P42574, P55957, P29353, P15056                                                                                                                                                                                                                                                                                                                                                                                                           6.88E-08
  hsa05160:hepatitis C                                                  24           3.39E-10        P23458, P42224, Q92934, P49841, O14920, P25963, P19525, P19838, P10398, O15111, P04637, P04049, O15551, O15530, P52630, P31751, Q04206, P38936, Q16539, P00533, Q9Y6K9, P31749, P40763, P15056                                                                                                                                                                                                                                                                                                                                                                                                           4.24E-07
  hsa04662:B cell receptor signaling pathway                            23           1.31E-15        Q15653, P49841, O14920, P25963, P52735, Q02750, P19838, Q06187, Q8WV28, P63000, O15111, P04049, P05412, P16885, P31751, P43405, Q04206, Q12968, P01100, O00221, Q9Y6K9, P31749, P07948                                                                                                                                                                                                                                                                                                                                                                                                                   1.67E-12
  hsa04064:NF-kappa B signaling pathway                                 23           2.76E-13        P06239, P05362, O14920, P25963, P67870, P19174, P19838, Q06187, O43561, Q8WV28, O15111, O43318, Q07817, Q04759, Q01201, P43403, P16885, P43405, P98170, Q04206, Q9Y6K9, P07948, P10415                                                                                                                                                                                                                                                                                                                                                                                                                   3.45E-10
  hsa05231:choline metabolism in cancer                                 23           7.19E-12        P23443, P17252, P16234, P19174, P49815, Q13541, Q02750, P05771, P47712, P63000, P04049, Q13393, P05412, Q92558, O15530, P09619, P31751, P42345, P08047, P00533, P01100, Q9UBS0, P31749                                                                                                                                                                                                                                                                                                                                                                                                                   8.99E-09
  hsa04152:AMPK signaling pathway                                       23           3.62E-10        Q13131, Q15831, P24385, P23443, P49815, Q13541, Q12778, P35568, P16220, Q05469, O43524, O43318, Q96B36, P08069, Q13085, P36956, O15530, P31751, O00418, P37231, P42345, Q9UBS0, P31749                                                                                                                                                                                                                                                                                                                                                                                                                   4.54E-07
  hsa04630:Jak-STAT signaling pathway                                   23           1.07E-08        P24385, P15260, P24394, P23458, P42224, P78552, P42226, P42229, Q07817, P19235, O60674, P52630, O75886, P51692, Q13651, P31751, Q06124, P26951, P01589, P01106, P30281, P31749, P40763                                                                                                                                                                                                                                                                                                                                                                                                                   1.33E-05
  hsa05152:tuberculosis                                                 23           4.11E-07        P15260, P42224, P23458, P12931, Q92934, P19838, P16220, P62158, P04049, O60674, Q13651, P31751, Q9UQM7, P43405, Q13158, Q04206, P42574, Q8IVT5, P55957, Q16539, P55211, P31749, P10415                                                                                                                                                                                                                                                                                                                                                                                                                   5.14E-04
  hsa05168:herpes simplex infection                                     23           7.36E-07        P15260, P42224, P23458, Q15653, O14920, P25963, P19525, P67870, P19838, P24941, O15111, P62136, P04637, O43318, P05412, O60674, P52630, Q13158, Q06124, Q04206, P42574, P01100, Q9Y6K9                                                                                                                                                                                                                                                                                                                                                                                                                   9.21E-04
  hsa05221:acute myeloid leukemia                                       22           1.22E-16        P24385, Q92934, P23443, O14920, Q13541, Q02750, P19838, P10398, P42229, O15111, P10721, P04049, P51692, P31751, Q04206, P01106, P42345, Q9Y6K9, Q9UBS0, P31749, P40763, P15056                                                                                                                                                                                                                                                                                                                                                                                                                           1.44E-13
  hsa04664:Fc epsilon RI signaling pathway                              22           1.21E-14        Q9UQC2, P17252, P52735, P19174, Q02750, P05771, Q06187, O43561, P47712, P63000, P04049, Q13094, O15530, P16885, P31751, P43405, P45985, Q16539, O14733, P46734, P31749, P07948                                                                                                                                                                                                                                                                                                                                                                                                                           1.51E-11
  hsa04071:sphingolipid signaling pathway                               22           1.65E-09        Q9UQC2, P17252, Q02750, Q01970, P05771, P19838, Q02156, P63000, P04637, P04049, Q13393, Q99683, O15530, P29474, P31751, Q04206, P55957, Q16539, P60484, P31749, Q05513, P10415                                                                                                                                                                                                                                                                                                                                                                                                                           2.06E-06
  hsa05223:non-small cell lung cancer                                   21           2.13E-15        P06400, P24385, Q13043, Q92934, P17252, Q9UM73, P19174, Q02750, P05771, P10398, O43524, P04637, P04049, O15530, P16885, P04626, P31751, P00533, P31749, P55211, P15056                                                                                                                                                                                                                                                                                                                                                                                                                                   2.64E-12
  hsa05210:colorectal cancer                                            21           2.07E-14        P24385, Q92934, P49841, Q02750, P10398, P84022, P35222, P63000, P04637, O15392, P04049, P05412, Q15796, P31751, P01106, P42574, P01100, P55211, P31749, P15056, P10415                                                                                                                                                                                                                                                                                                                                                                                                                                   2.58E-11
  hsa05222:small cell lung cancer                                       21           1.48E-11        P06400, P24385, P05556, O14920, P25963, P24864, P19838, P24941, O15111, P04637, Q07817, Q05397, P31751, P98170, Q04206, P01106, P60484, Q9Y6K9, P55211, P31749, P10415                                                                                                                                                                                                                                                                                                                                                                                                                                   1.86E-08
  hsa04912:GnRH signaling pathway                                       21           5.67E-11        P18848, P12931, P19419, Q14289, P17252, Q01970, Q02750, P05771, Q05655, P47712, P62158, P04049, Q13393, P05412, Q9UQM7, P45985, Q16539, P17612, O14733, P00533, P46734                                                                                                                                                                                                                                                                                                                                                                                                                                   7.10E-08
  hsa04670:leukocyte transendothelial migration                         21           7.30E-09        P18206, P05556, Q14289, P05362, P17252, P16284, P52735, P19174, P05771, P35222, P63000, O15551, P56945, P50552, P15311, Q05397, P49023, P16885, O60716, Q06124, Q16539                                                                                                                                                                                                                                                                                                                                                                                                                                   9.13E-06
  hsa04150:mTOR signaling pathway                                       20           6.91E-14        Q13131, Q15831, P23443, P17252, O14920, P49815, Q13541, P62753, P05771, P35568, P06730, Q96B36, Q15418, O15530, P31751, P42345, P60484, Q9UBS0, P31749, P15056                                                                                                                                                                                                                                                                                                                                                                                                                                           8.66E-11
  hsa05218:melanoma                                                     20           4.13E-12        P06400, P24385, Q92934, P11362, P08581, P16234, Q02750, P10398, O75030, P04637, P08069, P04049, Q00987, P09619, P31751, P38936, P60484, P00533, P31749, P15056                                                                                                                                                                                                                                                                                                                                                                                                                                           5.16E-09
  hsa04917:prolactin signaling pathway                                  20           4.13E-12        P24385, P42224, P12931, P49841, Q02750, P19838, P42229, O43524, P04049, P07101, P03372, O60674, P51692, P31751, Q04206, Q16539, P01100, P31749, P40763, P29353                                                                                                                                                                                                                                                                                                                                                                                                                                           5.16E-09
  hsa04915:estrogen signaling pathway                                   20           2.03E-09        P18848, P12931, P15336, Q01970, Q02750, Q05655, P16220, P62158, P04049, P05412, P03372, P08238, P29474, P31751, P17612, P08047, P01100, P00533, P31749, P29353                                                                                                                                                                                                                                                                                                                                                                                                                                           2.54E-06
  hsa04620:toll-like receptor signaling pathway                         20           6.73E-09        P41279, P42224, O14920, P25963, Q02750, P19838, P63000, O15111, O43318, P05412, P31751, Q13158, Q04206, P45985, Q16539, O14733, P01100, Q9Y6K9, P46734, P31749                                                                                                                                                                                                                                                                                                                                                                                                                                           8.42E-06
  hsa05213:endometrial cancer                                           19           1.07E-13        P24385, Q92934, P49841, P19419, Q02750, P10398, P35222, O43524, P04637, P04049, O15530, P04626, P31751, P01106, P60484, P00533, P55211, P31749, P15056                                                                                                                                                                                                                                                                                                                                                                                                                                                   1.34E-10
  hsa04370:VEGF signaling pathway                                       19           2.46E-12        P12931, Q92934, P17252, P19174, Q02750, P05771, P47712, P63000, P04049, P35968, Q05397, P49023, P16885, P29474, P31751, Q16539, P04792, P31749, P55211                                                                                                                                                                                                                                                                                                                                                                                                                                                   3.08E-09
  hsa04210:apoptosis                                                    19           3.35E-12        Q92934, O14920, P25963, P19838, O15111, P04637, Q07817, P31751, Q13158, P98170, Q04206, P26951, P42574, P55957, Q9Y6K9, P31749, P55211, P55212, P10415                                                                                                                                                                                                                                                                                                                                                                                                                                                   4.19E-09
  hsa05120:epithelial cell signaling in Helicobacter pylori infection   19           1.44E-11        Q13153, P12931, O14920, P25963, P08581, P19174, P19838, P63000, O15111, P05412, P16885, Q06124, Q04206, P45985, P42574, Q16539, P00533, Q9Y6K9, P07948                                                                                                                                                                                                                                                                                                                                                                                                                                                   1.80E-08
  hsa04728:dopaminergic synapse                                         19           7.83E-07        P18848, P49841, P17252, P15336, Q01970, P05771, P42262, P62136, P62158, P16220, P42261, P07101, P31751, Q9UQM7, Q13224, Q16539, P17612, P01100, P31749                                                                                                                                                                                                                                                                                                                                                                                                                                                   9.80E-04
  hsa04720:long-term potentiation                                       18           1.13E-10        P18848, P17252, Q05586, Q02750, Q01970, P05771, P10398, P42262, Q16566, P62136, P62158, P42261, P04049, Q15418, Q9UQM7, Q13224, P17612, P15056                                                                                                                                                                                                                                                                                                                                                                                                                                                           1.41E-07
  hsa05031:amphetamine addiction                                        18           1.13E-10        P18848, P17252, Q05586, P15336, P05771, P42262, Q16566, P62136, P62158, P16220, P42261, P05412, P07101, Q9UQM7, Q13224, P17612, P01100, P53539                                                                                                                                                                                                                                                                                                                                                                                                                                                           1.41E-07
  hsa04920:adipocytokine signaling pathway                              18           3.10E-10        Q13131, Q15831, Q15653, O14920, P25963, P19838, P35568, O15111, Q04759, O60674, P31751, Q06124, Q04206, P42345, Q9Y6K9, O00221, P31749, P40763                                                                                                                                                                                                                                                                                                                                                                                                                                                           3.88E-07
  hsa05142:Chagas disease (American trypanosomiasis)                    18           1.76E-07        P15260, P20963, O14920, P25963, Q01970, P19838, P84022, O15111, P05412, Q15796, P31751, Q13158, Q04206, P45985, Q16539, P01100, Q9Y6K9, P31749                                                                                                                                                                                                                                                                                                                                                                                                                                                           2.21E-04
  hsa04611:platelet activation                                          18           4.45E-06        P05556, P12931, Q01970, Q06187, P05106, P47712, P62136, Q13094, P50552, P16885, P29474, P31751, P43405, Q16539, P17612, P31749, Q05513, P07948                                                                                                                                                                                                                                                                                                                                                                                                                                                           0.00556524
  hsa05014:amyotrophic lateral sclerosis (ALS)                          17           1.05E-11        P29466, Q92934, Q05586, P04040, P42262, P63000, P04637, P42261, Q07817, Q99683, P42574, P55957, Q16539, Q13224, P46734, P55211, P10415                                                                                                                                                                                                                                                                                                                                                                                                                                                                   1.32E-08
  hsa05131:shigellosis                                                  16           6.03E-09        P18206, P12931, P05556, Q15653, O14920, P25963, P19838, P00519, O15111, P63000, Q92558, Q04206, Q16539, P46108, Q9Y6K9, Q14247                                                                                                                                                                                                                                                                                                                                                                                                                                                                           7.55E-06
  hsa05230:central carbon metabolism in cancer                          16           6.03E-09        P11362, P08581, P16234, Q02750, P04637, P10721, P04049, P09619, P04626, P31751, P01106, P42345, P60484, P00533, P07949, P31749                                                                                                                                                                                                                                                                                                                                                                                                                                                                           7.55E-06
  hsa05100:bacterial invasion of epithelial cells                       16           1.04E-07        P18206, P12931, P05556, P08581, P35222, Q03135, P63000, Q05193, Q13480, Q92558, P56945, Q05397, P49023, P46108, P29353, Q14247                                                                                                                                                                                                                                                                                                                                                                                                                                                                           1.30E-04
  hsa04925:aldosterone synthesis and secretion                          16           1.76E-07        P18846, P18848, P17252, P15336, Q01970, P05771, Q16566, Q02156, Q05469, P62158, P16220, Q14012, Q15139, Q9UQM7, Q9BZL6, P17612                                                                                                                                                                                                                                                                                                                                                                                                                                                                           2.20E-04
  hsa04914:progesterone-mediated oocyte maturation                      16           4.67E-07        Q02750, P24941, P10398, P08069, Q15418, P14635, P04049, P08238, P31751, P30305, P30304, Q16539, P17612, P30307, P31749, P15056                                                                                                                                                                                                                                                                                                                                                                                                                                                                           5.85E-04
  hsa04750:inflammatory mediator regulation of TRP channels             16           2.26E-06        P12931, P17252, P19174, Q01970, P05771, Q05655, P47712, P62136, P62158, Q02156, Q04759, P16885, Q9UQM7, Q16539, P17612, P46734                                                                                                                                                                                                                                                                                                                                                                                                                                                                           0.00282711
  hsa05211:renal cell carcinoma                                         15           6.24E-08        Q13153, P08581, Q02750, Q13177, P10398, P63000, P04049, Q13480, P05412, P31751, Q06124, O75914, P46108, P31749, P15056                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   7.81E-05
  hsa04115:p53 signaling pathway                                        15           9.37E-08        P24385, O14757, P24864, P49815, O96017, P24941, P04637, P14635, Q00987, P38936, P42574, P55957, P60484, P30281, P55211                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   1.17E-04
  hsa04520:adherens junction                                            15           2.02E-07        P18206, P12931, P11362, P08581, P67870, P84022, P35222, P63000, O43318, P08069, Q92558, Q15796, P04626, O60716, P00533                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   2.53E-04
  hsa05219:bladder cancer                                               14           1.10E-09        P06400, P24385, P12931, Q02750, P10398, P04637, P04049, Q00987, P04626, P01106, P38936, O75582, P00533, P15056                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           1.38E-06
  hsa05140:Leishmaniasis                                                14           1.36E-06        P15260, P42224, P23458, P05556, Q15653, P19419, P25963, P19838, O43318, P05412, O60674, Q04206, Q16539, P01100                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           0.00170437
  hsa05030:cocaine addiction                                            12           1.08E-06        P05412, P07101, P18848, Q04206, Q05586, P15336, P17612, Q13224, P19838, P42262, P53539, P16220                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           0.00135319

###### 

KEGG pathway enrichment of differentially expressed phosphorylated proteins by DAVID

  **Pathway term**                                                      **Count**   ***P*-value†**   **Swiss prot**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           **FDR**
  --------------------------------------------------------------------- ----------- ---------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------
  hsa05200:pathways in cancer                                           73          1.09E-32         P24385, P42224, Q13043, Q92769, P16234, Q01970, P10398, P84022, Q12778, P42229, P11274, Q00987, P16885, P38936, P17612, P55211, P10415, P15056, P06400, P05556, P49841, Q92934, P25963, P24864, P00519, P05771, P63000, P04637, P08069, P05412, Q07817, P08238, P98170, Q04206, P55957, P60484, P46527, P07333, P11362, P08581, O14920, P17252, Q02750, P35222, O75030, O15111, Q13547, P10275, P09619, P51692, P04626, P31751, Q13158, P01106, P42345, P37231, P01100, Q9Y6K9, P46108, P07949, P23458, P19174, P19838, P24941, O15392, P10721, P04049, Q15796, Q05397, P42574, P00533, P40763, P31749   1.36E-29
  hsa04012:ErbB signaling pathway                                       39          2.16E-32         P12931, P23443, P19419, P17252, Q02750, P10398, P42229, P42684, P16885, P51692, P04626, Q9UQM7, P31751, P38936, P01106, P42345, O75914, P46108, P29353, P15056, Q13153, P49841, Q92934, P19174, Q13541, P05771, P00519, Q13177, Q13480, P04049, P05412, Q05397, P45985, P21860, P00533, O14733, Q9UBS0, P46527, P31749                                                                                                                                                                                                                                                                                   2.70E-29
  hsa05215:prostate cancer                                              39          3.68E-32         P24385, P11362, O14920, P16234, Q02750, P10398, Q12778, P35222, O15111, P10275, Q00987, O15530, P09619, P04626, P31751, P38936, P42345, Q9Y6K9, P55211, P10415, P15056, P06400, P18848, P49841, Q92934, P25963, P24864, P19838, P24941, P16220, P04637, P04049, P08069, P08238, Q04206, P60484, P00533, P46527, P31749                                                                                                                                                                                                                                                                                   4.60E-29
  hsa04151:PI3K-Akt signaling pathway                                   68          6.55E-32         P24385, P16234, P49815, P62753, P35568, O15530, Q00987, P38936, P55211, P10415, O43521, Q16543, P24394, P05556, P49841, Q92934, P24864, P17948, P05106, O43524, P63000, P16220, P04637, P08069, Q07817, P35968, P08238, Q04206, P26951, P01589, P60484, Q9UBS0, P46527, Q15831, P07333, P23443, P11362, P08581, O14920, P17252, Q02750, O15111, O60674, P38398, P09619, P29474, P31751, P43405, P01106, P42345, P30281, Q9Y6K9, P63104, Q13131, P23458, P18848, Q13541, P16144, P15336, P19838, P24941, P06730, P10721, P04049, P19235, Q05397, P00533, P31749                                           8.20E-29
  hsa05161:hepatitis B                                                  45          1.88E-29         P24385, P42224, P12931, Q14289, P19419, P17252, O14920, Q02750, P42226, P42229, O15111, P51692, P31751, Q13158, P38936, P01106, Q12968, P01100, Q9Y6K9, P55211, P10415, P63104, P06400, P23458, P18848, Q92934, P25963, P24864, P15336, P05771, P19838, P24941, P16220, P04637, O15392, P04049, P05412, P52630, Q04206, P45985, P42574, P60484, P46527, P31749, P40763                                                                                                                                                                                                                                   2.36E-26
  hsa05205:proteoglycans in cancer                                      50          5.08E-28         P24385, P12931, P19419, P62753, P10398, Q03135, P62136, P15311, Q00987, O15530, P16885, Q9UQM7, P38936, P17612, P15056, P05556, Q13153, P21333, P17844, P05771, P05106, P63000, P04637, P08069, P35968, Q16539, Q9UBS0, P23443, P11362, P08581, P17252, Q02750, P35222, P04626, Q06124, P31751, P01106, P42345, P19174, Q13480, P04049, P03372, P49023, Q05397, P21860, P42574, P00533, P31749, P40763, Q14247                                                                                                                                                                                           6.36E-25
  hsa04010:MAPK signaling pathway                                       55          1.69E-27         Q13043, P19419, P16234, P28562, O43318, Q99683, P30305, P17612, P15056, Q13153, Q9BUB5, P21333, P05771, P47712, P63000, P04637, Q15418, P05412, Q01201, P16949, Q04206, P45985, Q16539, P04792, P49407, P11362, O14920, P17252, Q02750, O15111, P09619, P31751, P17535, P01106, Q12968, P11831, P01100, P46108, Q9Y6K9, P46734, P41279, P10636, P18848, Q13972, P15336, P19838, Q13177, P04049, Q16620, Q06413, P42574, O75582, O14733, P00533, P31749                                                                                                                                                   2.12E-24
  hsa04722:neurotrophin signaling pathway                               39          3.04E-26         P52565, O14920, Q02750, P35568, P62158, O15530, Q99683, P16885, Q06124, Q9UQM7, P31751, O00221, P46108, P29353, P10415, P15056, P18848, Q15653, P49841, Q92934, P25963, P19174, Q05655, P19838, P00519, Q16566, P63000, O43524, P04637, Q13480, Q15418, P04049, P05412, Q16620, Q04206, O75582, Q16539, O14733, P31749                                                                                                                                                                                                                                                                                   3.80E-23
  hsa05220:chronic myeloid leukemia                                     31          5.91E-25         P24385, Q92769, O14920, Q02750, P10398, P42229, O15111, Q13547, P11274, Q00987, P51692, Q06124, P31751, P38936, P01106, Q9Y6K9, P46108, P29353, P15056, P06400, Q9UQC2, Q92934, P25963, P19838, P00519, P04637, P04049, Q07817, Q04206, P46527, P31749                                                                                                                                                                                                                                                                                                                                                   7.40E-22
  hsa04014:Ras signaling pathway                                        49          1.76E-24         Q13043, P07333, P19419, P11362, P17252, P08581, O14920, Q05586, P16234, Q02750, O15111, P62158, P42684, P09619, P43403, P16885, P31751, Q06124, P17612, O75914, P98177, Q9Y6K9, P29353, Q04864, Q9UQC2, Q13153, Q92934, Q13972, P19174, P17948, P05771, P19838, Q13177, P00519, O43561, P47712, P63000, P10721, Q13480, P04049, P08069, Q13393, Q07817, P35968, Q04206, Q8IVT5, Q13224, P00533, P31749                                                                                                                                                                                                   2.20E-21
  hsa04510:focal adhesion                                               46          1.70E-23         P24385, P18206, P12931, P19419, P17252, P08581, P16234, Q02750, P35222, Q03135, P62136, P56945, O15530, P09619, P04626, P31751, P30281, O75914, P46108, P29353, P10415, P15056, P05556, Q13153, Q92934, P49841, Q13972, P52735, P21333, P16144, P17948, P05771, Q13177, P05106, P63000, P04049, P08069, P05412, P35968, P50552, Q05397, P49023, P98170, P60484, P00533, P31749                                                                                                                                                                                                                           2.13E-20
  hsa05169:Epstein-Barr virus infection                                 44          4.09E-23         Q92769, O14920, P67870, O15111, Q13547, O43318, Q00987, P16885, P56524, Q13651, P43405, P31751, P38936, P01106, P17612, O00221, Q9Y6K9, P46734, P10415, P63104, P07948, P06400, P23458, Q15653, P49841, P05362, P25963, P19525, P15336, P19174, P19838, P24941, P04637, P05412, Q01201, Q9UQL6, Q04206, P45985, Q16539, O14733, P04792, P40763, P46527, P31749                                                                                                                                                                                                                                           5.11E-20
  hsa04660:T cell receptor signaling pathway                            33          6.49E-22         P20963, P06239, P01730, O14920, Q02750, O15111, O43318, Q13094, O15530, P43403, P31751, Q12968, O75914, P01100, O00221, Q9Y6K9, P41279, Q13153, Q15653, P49841, P25963, P52735, P19174, P19838, Q13177, O43561, P04049, P05412, Q04759, Q04206, Q16539, O14733, P31749                                                                                                                                                                                                                                                                                                                                   8.12E-19
  hsa04380:osteoclast differentiation                                   36          1.81E-21         P17275, P06239, P42224, P07333, O14920, Q02750, Q06187, O75030, O15111, O43318, Q13094, P16885, P43405, P31751, P17535, P37231, P01100, Q9Y6K9, P15260, Q9UQC2, P23458, P25963, P19838, P05106, Q16566, Q8WV28, P16220, P63000, P05412, Q01201, P52630, Q04206, Q16539, P53539, O14733, P31749                                                                                                                                                                                                                                                                                                           2.27E-18
  hsa05203:viral carcinogenesis                                         41          4.83E-19         P24385, P12931, Q92769, Q9UBN7, O15379, P42229, Q13547, Q00987, P56524, P51692, P43405, P38936, P17612, P11831, P30281, Q9Y6K9, P63104, P07948, Q04864, P06400, O14757, P23458, P18848, Q92934, P25963, P24864, P19525, P15336, P19838, P24941, P16220, P63000, P04637, P05412, P49023, Q9UQL6, Q9BY41, Q04206, P42574, P46527, P40763                                                                                                                                                                                                                                                                   6.04E-16
  hsa05212:pancreatic cancer                                            25          1.12E-18         P06400, P24385, P42224, P23458, Q92934, O14920, Q02750, P19838, P10398, P84022, O15111, P63000, P04637, P04049, Q07817, Q15796, P04626, P31751, Q04206, P00533, Q9Y6K9, P55211, P31749, P40763, P15056                                                                                                                                                                                                                                                                                                                                                                                                   1.41E-15
  hsa04666:Fc gamma R-mediated phagocytosis                             27          6.21E-18         P23443, P17252, Q02750, P23528, Q02156, P16885, P53667, P43405, P31751, P29966, P08631, P46108, P07948, Q9UQC2, Q13153, P52735, P19174, P05771, Q05655, O43561, P63000, P04049, Q92558, Q13393, P50552, Q9UBS0, P31749                                                                                                                                                                                                                                                                                                                                                                                   7.77E-15
  hsa05214:glioma                                                       24          1.85E-17         P06400, P24385, P17252, P16234, P19174, Q02750, P05771, P10398, P62158, P04637, P08069, P04049, Q00987, P09619, P16885, P31751, Q9UQM7, P38936, P42345, P60484, P00533, P31749, P29353, P15056                                                                                                                                                                                                                                                                                                                                                                                                           2.31E-14
  hsa04919:thyroid hormone signaling pathway                            30          2.67E-17         P24385, P42224, P12931, Q92769, P17252, O15379, P49815, Q01970, Q02750, Q12778, P35222, Q13547, O15530, Q00987, P16885, P31751, P01106, P17612, P42345, P55211, P49841, Q92934, P19174, P05771, P05106, P04637, P04049, P03372, P31749, Q15648                                                                                                                                                                                                                                                                                                                                                           3.34E-14
  hsa04062:chemokine signaling pathway                                  37          4.36E-17         P42224, P12931, Q14289, O14920, Q01970, Q02750, O15111, P56945, O60674, P51692, P31751, P08631, P17612, P46108, Q9Y6K9, P29353, P25098, P15056, P07948, Q13153, Q15653, P49841, P25963, P52735, Q05655, P19838, P63000, O43524, P04049, Q05397, P49023, P52630, Q04206, P49407, P31749, P40763, Q05513                                                                                                                                                                                                                                                                                                   5.45E-14
  hsa05221:acute myeloid leukemia                                       22          1.22E-16         P24385, Q92934, P23443, O14920, Q13541, Q02750, P19838, P10398, P42229, O15111, P10721, P04049, P51692, P31751, Q04206, P01106, P42345, Q9Y6K9, Q9UBS0, P31749, P40763, P15056                                                                                                                                                                                                                                                                                                                                                                                                                           1.44E-13
  hsa04068:FoxO signaling pathway                                       31          3.33E-16         P24385, Q15831, Q13043, O14920, Q02750, P04040, P10398, P35568, Q12778, P84022, O15111, Q00987, O15530, P31751, P38936, P98177, P15056, Q13131, O43521, P24941, O43524, P14635, P04049, P08069, Q15796, P60484, Q16539, P00533, P40763, P46527, P31749                                                                                                                                                                                                                                                                                                                                                   4.22E-13
  hsa05166:HTLV-I infection                                             42          3.86E-16         P24385, P06239, P19419, O14920, P16234, P84022, P35222, P42229, O15111, P09619, P51692, P31751, P38936, P01106, P17612, P11831, Q12968, P30281, P01100, Q9Y6K9, P06400, O14757, P18846, P23458, P18848, P49841, P05362, P25963, P15336, O96017, P19838, P16220, P04637, P05412, Q07817, Q15796, Q01201, Q04206, P98170, P45985, P01589, P31749                                                                                                                                                                                                                                                           4.22E-13
  hsa04066:HIF-1 signaling pathway                                      27          4.22E-16         P23443, P17252, Q02750, P62753, P16885, P04626, P29474, Q9UQM7, P31751, P38936, P42345, P10415, P15260, Q9BUB5, Q13541, P19174, P17948, P05771, P19838, P06730, P08069, Q04206, P00533, Q9UBS0, P46527, P31749, P40763                                                                                                                                                                                                                                                                                                                                                                                   5.55E-13
  hsa04015:Rap1 signaling pathway                                       38          4.93E-16         P12931, P07333, P11362, P17252, P08581, Q05586, P16234, Q01970, Q02750, P35222, P62158, Q13094, P56945, Q15139, P09619, O60716, P31751, P46108, P46734, P15056, P05556, P19174, P17948, P05771, O43561, P05106, P63000, P10721, P04049, P08069, P35968, P50552, Q9BZL6, Q13224, Q16539, P00533, P31749, Q05513                                                                                                                                                                                                                                                                                           5.55E-13
  hsa04910:insulin signaling pathway                                    31          8.97E-16         P23443, P19419, O14920, P49815, Q02750, P62753, P10398, P35568, Q12778, P62136, P62158, P36956, O15530, P31751, P17612, P42345, P46108, P29353, P15056, Q13131, P49841, Q92934, Q9BUB5, Q13541, Q05469, P06730, P04049, Q13085, Q9UBS0, P31749, Q05513                                                                                                                                                                                                                                                                                                                                                   1.11E-12
  hsa04662:B cell receptor signaling pathway                            23          1.31E-15         Q15653, P49841, O14920, P25963, P52735, Q02750, P19838, Q06187, Q8WV28, P63000, O15111, P04049, P05412, P16885, P31751, P43405, Q04206, Q12968, P01100, O00221, Q9Y6K9, P31749, P07948                                                                                                                                                                                                                                                                                                                                                                                                                   1.67E-12
  hsa05223:non-small cell lung cancer                                   21          2.13E-15         P06400, P24385, Q13043, Q92934, P17252, Q9UM73, P19174, Q02750, P05771, P10398, O43524, P04637, P04049, O15530, P16885, P04626, P31751, P00533, P31749, P55211, P15056                                                                                                                                                                                                                                                                                                                                                                                                                                   2.64E-12
  hsa04664:Fc epsilon RI signaling pathway                              22          1.21E-14         Q9UQC2, P17252, P52735, P19174, Q02750, P05771, Q06187, O43561, P47712, P63000, P04049, Q13094, O15530, P16885, P31751, P43405, P45985, Q16539, O14733, P46734, P31749, P07948                                                                                                                                                                                                                                                                                                                                                                                                                           1.51E-11
  hsa05210:colorectal cancer                                            21          2.07E-14         P24385, Q92934, P49841, Q02750, P10398, P84022, P35222, P63000, P04637, O15392, P04049, P05412, Q15796, P31751, P01106, P42574, P01100, P55211, P31749, P15056, P10415                                                                                                                                                                                                                                                                                                                                                                                                                                   2.58E-11
  hsa04668:TNF signaling pathway                                        26          3.48E-14         P17275, O14920, Q02750, O15111, O43318, Q99683, Q13158, P31751, P01100, P46734, Q9Y6K9, P41279, P18848, P05362, P25963, P15336, P19838, P16220, P05412, Q04206, P45985, P42574, Q16539, O75582, O14733, P31749                                                                                                                                                                                                                                                                                                                                                                                           4.35E-11
  hsa04931:insulin resistance                                           26          5.53E-14         P23443, O14920, Q12778, P35568, Q02156, P62136, P36956, O15530, P29474, Q06124, P31751, P42345, Q13131, P49841, P25963, Q05655, P19838, P16220, Q15418, Q04759, Q04206, P60484, Q9UBS0, P31749, P40763, Q05513                                                                                                                                                                                                                                                                                                                                                                                           6.92E-11
  hsa04150:mTOR signaling pathway                                       20          6.91E-14         Q13131, Q15831, P23443, P17252, O14920, P49815, Q13541, P62753, P05771, P35568, P06730, Q96B36, Q15418, O15530, P31751, P42345, P60484, Q9UBS0, P31749, P15056                                                                                                                                                                                                                                                                                                                                                                                                                                           8.66E-11
  hsa05206:microRNAs in cancer                                          41          7.89E-14         P24385, P17252, O14920, P08581, P16234, Q02750, P35568, Q02156, P15311, Q00987, P38398, P09619, P16885, P04626, P29966, P30305, P30304, P38936, P01106, P42345, P46108, P30307, P29353, P10415, O43521, P24864, P19174, P05771, P19838, P00519, P05106, P04637, P04049, P16949, P42574, P21860, O75582, P60484, P00533, P46527, P40763                                                                                                                                                                                                                                                                   9.86E-11
  hsa05213:endometrial cancer                                           19          1.07E-13         P24385, Q92934, P49841, P19419, Q02750, P10398, P35222, O43524, P04637, P04049, O15530, P04626, P31751, P01106, P60484, P00533, P55211, P31749, P15056                                                                                                                                                                                                                                                                                                                                                                                                                                                   1.34E-10
  hsa05162:measles                                                      28          1.60E-13         P24385, P42224, P67870, P42229, O15111, O43318, O60674, P51692, P31751, P30281, P15260, P23458, P49841, Q15653, P25963, P24864, P19525, P24941, P19838, Q99704, P04637, Q04759, P52630, Q04206, P01589, P40763, P46527, P31749                                                                                                                                                                                                                                                                                                                                                                           2.00E-10
  hsa04064:NF-kappa B signaling pathway                                 23          2.76E-13         P06239, P05362, O14920, P25963, P67870, P19174, P19838, Q06187, O43561, Q8WV28, O15111, O43318, Q07817, Q04759, Q01201, P43403, P16885, P43405, P98170, Q04206, Q9Y6K9, P07948, P10415                                                                                                                                                                                                                                                                                                                                                                                                                   3.45E-10
  hsa05145:toxoplasmosis                                                26          4.81E-13         P42224, O14920, O15111, O43318, O60674, O15530, Q13651, P31751, P46734, Q9Y6K9, P55211, P10415, P15260, P23458, P05556, Q15653, Q92934, P25963, P19838, Q07817, Q04206, P98170, P42574, Q16539, P40763, P31749                                                                                                                                                                                                                                                                                                                                                                                           6.02E-10
  hsa04110:cell cycle                                                   26          1.58E-12         P06400, P24385, O14757, Q92769, P49841, P24864, O96017, P00519, P24941, P84022, P50613, P78527, P04637, Q13547, P14635, Q15796, Q00987, Q14683, P30305, P30304, P01106, P38936, P30281, P30307, P46527, P63104                                                                                                                                                                                                                                                                                                                                                                                           1.97E-09
  hsa04370:VEGF signaling pathway                                       19          2.46E-12         P12931, Q92934, P17252, P19174, Q02750, P05771, P47712, P63000, P04049, P35968, Q05397, P49023, P16885, P29474, P31751, Q16539, P04792, P31749, P55211                                                                                                                                                                                                                                                                                                                                                                                                                                                   3.08E-09
  hsa04210:apoptosis                                                    19          3.35E-12         Q92934, O14920, P25963, P19838, O15111, P04637, Q07817, P31751, Q13158, P98170, Q04206, P26951, P42574, P55957, Q9Y6K9, P31749, P55211, P55212, P10415                                                                                                                                                                                                                                                                                                                                                                                                                                                   4.19E-09
  hsa05218:melanoma                                                     20          4.13E-12         P06400, P24385, Q92934, P11362, P08581, P16234, Q02750, P10398, O75030, P04637, P08069, P04049, Q00987, P09619, P31751, P38936, P60484, P00533, P31749, P15056                                                                                                                                                                                                                                                                                                                                                                                                                                           5.16E-09
  hsa04917:prolactin signaling pathway                                  20          4.13E-12         P24385, P42224, P12931, P49841, Q02750, P19838, P42229, O43524, P04049, P07101, P03372, O60674, P51692, P31751, Q04206, Q16539, P01100, P31749, P40763, P29353                                                                                                                                                                                                                                                                                                                                                                                                                                           5.16E-09
  hsa05231:choline metabolism in cancer                                 23          7.19E-12         P23443, P17252, P16234, P19174, P49815, Q13541, Q02750, P05771, P47712, P63000, P04049, Q13393, P05412, Q92558, O15530, P09619, P31751, P42345, P08047, P00533, P01100, Q9UBS0, P31749                                                                                                                                                                                                                                                                                                                                                                                                                   8.99E-09
  hsa05014:amyotrophic lateral sclerosis (ALS)                          17          1.05E-11         P29466, Q92934, Q05586, P04040, P42262, P63000, P04637, P42261, Q07817, Q99683, P42574, P55957, Q16539, Q13224, P46734, P55211, P10415                                                                                                                                                                                                                                                                                                                                                                                                                                                                   1.32E-08
  hsa05120:epithelial cell signaling in Helicobacter pylori infection   19          1.44E-11         Q13153, P12931, O14920, P25963, P08581, P19174, P19838, P63000, O15111, P05412, P16885, Q06124, Q04206, P45985, P42574, Q16539, P00533, Q9Y6K9, P07948                                                                                                                                                                                                                                                                                                                                                                                                                                                   1.80E-08
  hsa05222:small cell lung cancer                                       21          1.48E-11         P06400, P24385, P05556, O14920, P25963, P24864, P19838, P24941, O15111, P04637, Q07817, Q05397, P31751, P98170, Q04206, P01106, P60484, Q9Y6K9, P55211, P31749, P10415                                                                                                                                                                                                                                                                                                                                                                                                                                   1.86E-08
  hsa04650:natural killer cell mediated cytotoxicity                    24          5.50E-11         P15260, P20963, P06239, Q13153, Q14289, P05362, P17252, P52735, P19174, Q02750, P05771, P10398, O43561, P63000, P04049, Q13094, P43403, P16885, P43405, Q06124, P42574, P55957, P29353, P15056                                                                                                                                                                                                                                                                                                                                                                                                           6.88E-08
  hsa04912:GnRH signaling pathway                                       21          5.67E-11         P18848, P12931, P19419, Q14289, P17252, Q01970, Q02750, P05771, Q05655, P47712, P62158, P04049, Q13393, P05412, Q9UQM7, P45985, Q16539, P17612, O14733, P00533, P46734                                                                                                                                                                                                                                                                                                                                                                                                                                   7.10E-08
  hsa04720:long-term potentiation                                       18          1.13E-10         P18848, P17252, Q05586, Q02750, Q01970, P05771, P10398, P42262, Q16566, P62136, P62158, P42261, P04049, Q15418, Q9UQM7, Q13224, P17612, P15056                                                                                                                                                                                                                                                                                                                                                                                                                                                           1.41E-07
  hsa05031:amphetamine addiction                                        18          1.13E-10         P18848, P17252, Q05586, P15336, P05771, P42262, Q16566, P62136, P62158, P16220, P42261, P05412, P07101, Q9UQM7, Q13224, P17612, P01100, P53539                                                                                                                                                                                                                                                                                                                                                                                                                                                           1.41E-07
  hsa04920:adipocytokine signaling pathway                              18          3.10E-10         Q13131, Q15831, Q15653, O14920, P25963, P19838, P35568, O15111, Q04759, O60674, P31751, Q06124, Q04206, P42345, Q9Y6K9, O00221, P31749, P40763                                                                                                                                                                                                                                                                                                                                                                                                                                                           3.88E-07
  hsa05160:hepatitis C                                                  24          3.39E-10         P23458, P42224, Q92934, P49841, O14920, P25963, P19525, P19838, P10398, O15111, P04637, P04049, O15551, O15530, P52630, P31751, Q04206, P38936, Q16539, P00533, Q9Y6K9, P31749, P40763, P15056                                                                                                                                                                                                                                                                                                                                                                                                           4.24E-07
  hsa04152:AMPK signaling pathway                                       23          3.62E-10         Q13131, Q15831, P24385, P23443, P49815, Q13541, Q12778, P35568, P16220, Q05469, O43524, O43318, Q96B36, P08069, Q13085, P36956, O15530, P31751, O00418, P37231, P42345, Q9UBS0, P31749                                                                                                                                                                                                                                                                                                                                                                                                                   4.54E-07
  hsa05164:influenza A                                                  27          6.37E-10         P29466, P42224, P17252, O14920, Q02750, O60674, P31751, P46734, P55211, P15260, P23458, P49841, Q15653, P05362, P25963, P19525, P15336, P05771, P19838, P04049, P05412, P52630, Q04206, P45985, Q16539, O14733, P31749                                                                                                                                                                                                                                                                                                                                                                                   7.97E-07
  hsa05034:alcoholism                                                   27          9.33E-10         Q92769, Q9UBN7, O15379, Q05586, Q02750, Q71DI3, P10398, P62158, P62136, Q13547, P84243, P07101, P56524, P29353, P15056, P16104, P18848, P15336, Q16566, P16220, P04049, Q16620, Q9UQL6, Q9BY41, P68431, Q13224, P53539                                                                                                                                                                                                                                                                                                                                                                                   1.17E-06
  hsa05219:bladder cancer                                               14          1.10E-09         P06400, P24385, P12931, Q02750, P10398, P04637, P04049, Q00987, P04626, P01106, P38936, O75582, P00533, P15056                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           1.38E-06
  hsa05202:transcriptional misregulation in cancer                      26          1.52E-09         P07333, Q92769, P08581, Q15797, Q71DI3, Q12778, Q13547, P84243, Q00987, P38936, P01106, P37231, Q04864, P18846, P17948, P17844, P19838, P04637, P08069, Q07817, Q06413, Q05397, P68431, Q04206, P08047, P46527                                                                                                                                                                                                                                                                                                                                                                                           1.90E-06
  hsa04071:sphingolipid signaling pathway                               22          1.65E-09         Q9UQC2, P17252, Q02750, Q01970, P05771, P19838, Q02156, P63000, P04637, P04049, Q13393, Q99683, O15530, P29474, P31751, Q04206, P55957, Q16539, P60484, P31749, Q05513, P10415                                                                                                                                                                                                                                                                                                                                                                                                                           2.06E-06
  hsa04915:estrogen signaling pathway                                   20          2.03E-09         P18848, P12931, P15336, Q01970, Q02750, Q05655, P16220, P62158, P04049, P05412, P03372, P08238, P29474, P31751, P17612, P08047, P01100, P00533, P31749, P29353                                                                                                                                                                                                                                                                                                                                                                                                                                           2.54E-06
  hsa04921:oxytocin signaling pathway                                   25          2.15E-09         Q13131, P24385, P12931, P19419, P17252, Q01970, Q02750, P05771, Q16566, Q92736, P47712, P62158, P62136, P04049, P05412, Q14012, Q06413, P29474, Q9UQM7, O00418, P38936, Q12968, P17612, P00533, P01100                                                                                                                                                                                                                                                                                                                                                                                                   2.69E-06
  hsa05131:shigellosis                                                  16          6.03E-09         P18206, P12931, P05556, Q15653, O14920, P25963, P19838, P00519, O15111, P63000, Q92558, Q04206, Q16539, P46108, Q9Y6K9, Q14247                                                                                                                                                                                                                                                                                                                                                                                                                                                                           7.55E-06
  hsa05230:central carbon metabolism in cancer                          16          6.03E-09         P11362, P08581, P16234, Q02750, P04637, P10721, P04049, P09619, P04626, P31751, P01106, P42345, P60484, P00533, P07949, P31749                                                                                                                                                                                                                                                                                                                                                                                                                                                                           7.55E-06
  hsa04620:toll-like receptor signaling pathway                         20          6.73E-09         P41279, P42224, O14920, P25963, Q02750, P19838, P63000, O15111, O43318, P05412, P31751, Q13158, Q04206, P45985, Q16539, O14733, P01100, Q9Y6K9, P46734, P31749                                                                                                                                                                                                                                                                                                                                                                                                                                           8.42E-06
  hsa04670:leukocyte transendothelial migration                         21          7.30E-09         P18206, P05556, Q14289, P05362, P17252, P16284, P52735, P19174, P05771, P35222, P63000, O15551, P56945, P50552, P15311, Q05397, P49023, P16885, O60716, Q06124, Q16539                                                                                                                                                                                                                                                                                                                                                                                                                                   9.13E-06
  hsa04630:Jak-STAT signaling pathway                                   23          1.07E-08         P24385, P15260, P24394, P23458, P42224, P78552, P42226, P42229, Q07817, P19235, O60674, P52630, O75886, P51692, Q13651, P31751, Q06124, P26951, P01589, P01106, P30281, P31749, P40763                                                                                                                                                                                                                                                                                                                                                                                                                   1.33E-05
  hsa04024:cAMP signaling pathway                                       27          1.07E-08         Q05586, Q02750, P42262, P62158, P62136, Q9UQM7, P31751, P17612, P01100, P15056, Q13153, Q92934, P25963, P52735, P19838, Q16566, Q92736, Q05469, P63000, P16220, P42261, P04049, Q13393, P05412, Q04206, Q13224, P31749                                                                                                                                                                                                                                                                                                                                                                                   1.34E-05
  hsa04810:regulation of actin cytoskeleton                             27          4.08E-08         P18206, P12931, P11362, P16234, Q02750, P10398, P23528, P62136, P56945, P15311, P09619, P53667, O75914, P46108, P15056, P05556, Q13153, P52735, P16144, Q13177, P05106, P63000, P04049, Q92558, Q05397, P49023, P00533                                                                                                                                                                                                                                                                                                                                                                                   5.10E-05
  hsa05211:renal cell carcinoma                                         15          6.24E-08         Q13153, P08581, Q02750, Q13177, P10398, P63000, P04049, Q13480, P05412, P31751, Q06124, O75914, P46108, P31749, P15056                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   7.81E-05
  hsa04115:p53 signaling pathway                                        15          9.37E-08         P24385, O14757, P24864, P49815, O96017, P24941, P04637, P14635, Q00987, P38936, P42574, P55957, P60484, P30281, P55211                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   1.17E-04
  hsa05100:bacterial invasion of epithelial cells                       16          1.04E-07         P18206, P12931, P05556, P08581, P35222, Q03135, P63000, Q05193, Q13480, Q92558, P56945, Q05397, P49023, P46108, P29353, Q14247                                                                                                                                                                                                                                                                                                                                                                                                                                                                           1.30E-04
  hsa04925:aldosterone synthesis and secretion                          16          1.76E-07         P18846, P18848, P17252, P15336, Q01970, P05771, Q16566, Q02156, Q05469, P62158, P16220, Q14012, Q15139, Q9UQM7, Q9BZL6, P17612                                                                                                                                                                                                                                                                                                                                                                                                                                                                           2.20E-04
  hsa05142:Chagas disease (American trypanosomiasis)                    18          1.76E-07         P15260, P20963, O14920, P25963, Q01970, P19838, P84022, O15111, P05412, Q15796, P31751, Q13158, Q04206, P45985, Q16539, P01100, Q9Y6K9, P31749                                                                                                                                                                                                                                                                                                                                                                                                                                                           2.21E-04
  hsa04520:adherens junction                                            15          2.02E-07         P18206, P12931, P11362, P08581, P67870, P84022, P35222, P63000, O43318, P08069, Q92558, Q15796, P04626, O60716, P00533                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   2.53E-04
  hsa05152:tuberculosis                                                 23          4.11E-07         P15260, P42224, P23458, P12931, Q92934, P19838, P16220, P62158, P04049, O60674, Q13651, P31751, Q9UQM7, P43405, Q13158, Q04206, P42574, Q8IVT5, P55957, Q16539, P55211, P31749, P10415                                                                                                                                                                                                                                                                                                                                                                                                                   5.14E-04
  hsa04914:progesterone-mediated oocyte maturation                      16          4.67E-07         Q02750, P24941, P10398, P08069, Q15418, P14635, P04049, P08238, P31751, P30305, P30304, Q16539, P17612, P30307, P31749, P15056                                                                                                                                                                                                                                                                                                                                                                                                                                                                           5.85E-04
  hsa05168:herpes simplex infection                                     23          7.36E-07         P15260, P42224, P23458, Q15653, O14920, P25963, P19525, P67870, P19838, P24941, O15111, P62136, P04637, O43318, P05412, O60674, P52630, Q13158, Q06124, Q04206, P42574, P01100, Q9Y6K9                                                                                                                                                                                                                                                                                                                                                                                                                   9.21E-04
  hsa04728:dopaminergic synapse                                         19          7.83E-07         P18848, P49841, P17252, P15336, Q01970, P05771, P42262, P62136, P62158, P16220, P42261, P07101, P31751, Q9UQM7, Q13224, Q16539, P17612, P01100, P31749                                                                                                                                                                                                                                                                                                                                                                                                                                                   9.80E-04
  hsa05030:cocaine addiction                                            12          1.08E-06         P05412, P07101, P18848, Q04206, Q05586, P15336, P17612, Q13224, P19838, P42262, P53539, P16220                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           0.0013532
  hsa05140:Leishmaniasis                                                14          1.36E-06         P15260, P42224, P23458, P05556, Q15653, P19419, P25963, P19838, O43318, P05412, O60674, Q04206, Q16539, P01100                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           0.0017044
  hsa04750:inflammatory mediator regulation of TRP channels             16          2.26E-06         P12931, P17252, P19174, Q01970, P05771, Q05655, P47712, P62136, P62158, Q02156, Q04759, P16885, Q9UQM7, Q16539, P17612, P46734                                                                                                                                                                                                                                                                                                                                                                                                                                                                           0.0028271
  hsa04611:platelet activation                                          18          4.45E-06         P05556, P12931, Q01970, Q06187, P05106, P47712, P62136, Q13094, P50552, P16885, P29474, P31751, P43405, Q16539, P17612, P31749, Q05513, P07948                                                                                                                                                                                                                                                                                                                                                                                                                                                           0.0055652
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